美國
證券交易委員會 及交易所
華盛頓特區，20549
表單
截至年度季度結束
或
在________到________的過渡期間
委員會
檔案號碼：
(根據公司章程所述的註冊人的正確名稱)
（註冊地點或其他管轄區的州份 註冊或組織） |
（聯邦國稅局雇主身分識別號碼） 識別號碼） | |
| （總執行辦公室地址） | （郵政編碼） |
（申報人的電話號碼，包括區號）
根據該法案第12(b)條紀錄的證券：
| 每個類別的標題: | 交易標的: | 每個交易所的名稱: | ||
| |
勾選表示公司已按照證券交易法第13或15(d)條款的規定，在過去12個月（或公司需要提交此類報告的較短期限內）提交了所有所需的報告；並且公司在過去90天內一直受到此類提交報告的要求。
請勾選，指出在過去12個月內（或更短時間並應提供此類文件的情況下），申報人是否已依據Regulation S-t（本章節之§232.405號）提交每一個所需提交的互動式數據文件。
請勾選以下內容，以指示申報人是大型快速申報者、快速申報者、非快速申報者、較小的報告公司還是新興成長公司。請參見《交易所法》第120條第2款中對「大型快速申報者」、「快速申報者」、「較小的報告公司」和「新興成長公司」的定義：
| 大型 加速文件提交人 ☐ | 加速申報者 ☐ | |
| 較小的報告公司 | ||
| 新興成長型企業 |
若屬新興成長公司，則請在適用於依據第13(a)款擬定的任何新或修訂財務會計準則時，打勾表示註冊人已選擇不使用過度過渡期遵守該準則。 ☐
請勾選是否登記者為外殼公司（依照交易所法規120億2的定義）。是 ☐ 否
截至2024年11月11日，有 每股$ 的普通股 。
BEYOND AIR, INC.及其附屬公司
指數 表格10-Q申報
截至2024年9月30日止期
目 錄
| 頁面 | |
| 第一部分 財務資訊 | 3 |
| 項目 1. 精簡合併財務報表（未經審計） | 3 |
| 第2項。管理層對財務狀況和業務成果的討論與分析 | 28 |
| 項目3. 市場風險之定量與質化披露 | 38 |
| 第四項事項。控制和程序。 | 38 |
| 第二部分其他資訊 | 39 |
| 第一項。法律訴訟。 | 39 |
| 項目 1A. 風險因素 | 39 |
| 項目2. 未注冊出售股權及資金用途 | 39 |
| ITEm 3. Defaults Upon Senior Securities | 39 |
| 第4項 鉱山安全披露 | 39 |
| 第5項 其他資訊 | 39 |
| 項目6. 附件 | 40 |
| 簽名 | 41 |
| 2 |
第一部分 財務信息
項目 1. 基本報表。
簡明綜合基本報表（未經審核）
指数
| 頁面 | |
| 縮短的合併財務報表 | 4 |
| 綜合損益簡明綜合表 | 5 |
| 股東權益變動縮表(未經審計) | 6 |
| 簡明合併現金流量量表 | 8 |
| 附註至簡明綜合財務報表 | 9– 27 |
| 3 |
BEYOND AIR, INC.及其附屬公司
簡明合併資產負債表
（金額均以千元為單位，股份和每股資料除外）
| 2024年9月30日 | 二○二四年三月三十一日 | |||||||
| （未經 審核） | ||||||||
| 資產 | ||||||||
| 流動資產合計 | ||||||||
| 現金及其等效資產 | $ | $ | ||||||
| 有價證券 | ||||||||
| 限制性現金 | ||||||||
| 應收帳款 | ||||||||
| 存貨淨額 | ||||||||
| 其他 流動資產和預付費用 | ||||||||
| 全部流動資產 | ||||||||
| 使用技術的授權權利 | ||||||||
| 使用權租賃資產 | ||||||||
| 物業及設備，淨值 | ||||||||
| 其他資產 | ||||||||
| 總資產 | $ | $ | ||||||
| 負債及股東權益 | ||||||||
| 流動負債 | ||||||||
| 應付帳款 | $ | $ | ||||||
| 應計費用和其他 流動負債 | ||||||||
| 營業租賃負債， 目前部分 | ||||||||
| 貸款 應付，目前部分 | ||||||||
| 流動負債合計 | ||||||||
| 營業租賃負債，淨額 | ||||||||
| 長期負債淨額 | ||||||||
| 長期負債，相關方 | ||||||||
| 認股權負債 | ||||||||
| 衍生負債 | ||||||||
| 總負債 | ||||||||
| 股東權益 | ||||||||
| 每股面額$ 每股面額： 已授權股份， 股份發行及流通 | ||||||||
| 普通股，每股面值$ 每股面額： 已授權股份， 和 截至2024年9月30日和2024年3月31日期間已發行並流通的股份，分別為 | ||||||||
| 庫藏股 | ( | ) | ( | ) | ||||
| 資本公積額額外增資 | ||||||||
| 累積虧損 | ( | ) | ( | ) | ||||
| 累積其他綜合收益（損失） | ( | ) | ||||||
| Beyond Air, Inc歸屬於股東的總資產 | ||||||||
| 非控制權益 | ||||||||
| 總權益 | ||||||||
| 總負債和股東權益 | $ | $ | ||||||
隨附註釋為這些未經審計的縮短綜合財務報表的一個重要組成部分。
| 4 |
BEYOND AIR, INC.及其附屬公司
綜合損益表簡明合併陳述
（金額均以千元為單位，股份和每股資料除外）
(未經查核)
| 三個月結束時 | 截至六個月結束 | |||||||||||||||
| 九月 30日, | 九月 30日, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| 營收 | $ | $ | $ | $ | ||||||||||||
| 銷貨成本 | ||||||||||||||||
| 毛損失 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| 營業費用： | ||||||||||||||||
| 研發 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| 銷售、總體和行政 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| 營業費用總額 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| 營運虧損 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| 其他收入（費用） | ||||||||||||||||
| 股息/利息收入 | ||||||||||||||||
| 利息和財務費用 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| 認股權憑證負債公允價值變動 | ( | ) | ||||||||||||||
| 衍生負債公允價值變化 | ||||||||||||||||
| 匯率期貨收益/（虧損） | ( | ) | ( | ) | ( | ) | ||||||||||
| 償還債務損失 | ( | ) | ( | ) | ||||||||||||
| 處置固定資產損失 | ( | ) | ( | ) | ||||||||||||
| 預估應付可能損失 | ( | ) | ( | ) | ||||||||||||
| 其他收入 / (費用) | ( | ) | ||||||||||||||
| 總計其他收入/（費用） | ( | ) | ( | ) | ||||||||||||
| 收入稅前淨損失 | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| 所得税费用 | ||||||||||||||||
| 淨虧損 | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| 较少：归属于非控股股东的净损失 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| 归属於Beyond Air, Inc.的净亏损 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| 外幣翻譯損失 | ( | ) | ( | ) | ( | ) | ||||||||||
| 综合亏损归属於Beyond Air, Inc. | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| 基本和稀释後每股净亏损归属於Beyond Air, Inc. | $ | ) | $ | ) | $ | ) | $ | ) | ||||||||
| 加权平均股份，流通，基本和稀释 | ||||||||||||||||
隨附註釋為這些未經審計的縮短綜合財務報表的一個重要組成部分。
| 5 |
BEYOND AIR, INC.及其附屬公司
股東權益變動總表
(未經查核)
截至2024年9月30日止三個及六個月
(金額以千為單位，除每股數據外)
| 普通股 | 庫藏 | 額外 實收 | 累積 | 累積 其他 綜合 | Non- 控制權 | 總數 | ||||||||||||||||||||||||||
| 數字 | 金額 | 股票 | 資本 | 赤字 | 收益 | 利息 | 資產 | |||||||||||||||||||||||||
| 截至2024年4月1日的結餘 | $ | | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | $ | $ | ||||||||||||||||||
| 普通股認股權證的發行 | - | |||||||||||||||||||||||||||||||
| 基於股票的補償 | - | |||||||||||||||||||||||||||||||
| 其他綜合收益 | - | |||||||||||||||||||||||||||||||
| 淨虧損 | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| 截至2024年6月30日的餘額 | $ | $ | ( | ) | $ | $ | ( | ) | $ | $ | $ | |||||||||||||||||||||
| 普通股 | 庫藏 | 額外 實收 | 累積 | 累積 其他 綜合 | Non- 控制權 | 總數 | ||||||||||||||||||||||||||
| 數字 | 金額 | 股票 | 資本 | 赤字 | 損失 | 利息 | 資產 | |||||||||||||||||||||||||
| 截至2024年7月1日的結餘 | $ | | $ | ( | ) | $ | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||
| 普通股及預先融資認股權的銷售 | ||||||||||||||||||||||||||||||||
透過2024年9月債務協議發行認股權 | ||||||||||||||||||||||||||||||||
| 通過市場股本證券發行普通股，淨額 | ||||||||||||||||||||||||||||||||
| 基於股票的補償 | - | |||||||||||||||||||||||||||||||
| 其他綜合損失 | - | ( | ) | ( | ) | |||||||||||||||||||||||||||
| 淨虧損 | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| 截至2024年9月30日的餘額 | $ | $ | ( | ) | $ | $ | ( | ) | $ | $ | $ | |||||||||||||||||||||
| 6 |
BEYOND AIR, INC.及其附屬公司
股東權益變動總表
(未經查核)
截至2023年9月30日止三個月和六個月
(金額以千為單位，除每股數據外)
| 普通股 | 庫藏 | 額外 實收 | 累積 | 累積 其他 綜合 | Non- 控制權 | 總數 | ||||||||||||||||||||||||||
| 數字 | 金額 | 股票 | 資本 | 赤字 | 收益 | 利息 | 資產 | |||||||||||||||||||||||||
| 截至2023年4月1日的結餘 | $ | | $ | ( | ) | $ | $ | ( | ) | $ | | $ | $ | |||||||||||||||||||
| 行使期權後發行普通股 | ||||||||||||||||||||||||||||||||
| 在市場上股權發行普通股的募集中，淨額 | ||||||||||||||||||||||||||||||||
| 基於股票的補償 | - | |||||||||||||||||||||||||||||||
| 其他綜合收益 | - | |||||||||||||||||||||||||||||||
| 淨虧損 | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| 截至2023年6月30日的結餘 | $ | $ | ( | ) | $ | $ | ( | ) | $ | $ | $ | |||||||||||||||||||||
| 普通股 | 庫藏 | 額外 實收 | 累計 | 累計 其他 綜合 | Non- 控制權 | 總計 | ||||||||||||||||||||||||||
| 數量 | 金額 | 股票 | 資本 | 赤字 | 收益 | 利息 | 權益 | |||||||||||||||||||||||||
| 截至2023年7月1日的結餘 | $ | | $ | ( | ) | $ | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||
| 行使期權後發行普通股 | - | |||||||||||||||||||||||||||||||
| 在市場股權發售股票發行 普通股股票，淨值 | ||||||||||||||||||||||||||||||||
| 以股票為基礎的薪資 | - | |||||||||||||||||||||||||||||||
| 其他綜合收益 | - | ( | ) | ( | ) | |||||||||||||||||||||||||||
| 淨虧損 | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| 2023年9月30日的結餘 | $ | $ | ( | ) | $ | $ | ( | ) | $ | $ | $ | |||||||||||||||||||||
隨附註釋為這些未經審計的縮短綜合財務報表的一個重要組成部分。
| 7 |
BEYOND AIR, INC. 及其附屬公司
未經審計的綜合現金流量表縮編
(數量 以千為單位)
| 截至六個月結束 | ||||||||
| 九月 30日, | ||||||||
| 2024 | 2023 | |||||||
| 來自 營運活動的現金流量 | ||||||||
| 淨虧損 | $ | ( | ) | $ | ( | ) | ||
| 調整以調解 淨損失到在營運活動使用的淨現金 | ||||||||
| 折舊和攤銷 | ||||||||
| 對使用的授權 科技的攤銷 | ||||||||
| 基於股票的補償 | ||||||||
| 債務折價攤銷 | ||||||||
| warrants責任券公平價值變動 | ( | ) | ( | ) | ||||
| 衍生責任公平價值變動 | ( | ) | ( | ) | ||||
| 營運租賃資產攤銷 | ||||||||
| 外匯調整 | ||||||||
| 債務清償損失 | ||||||||
| 使用權資產終止損失 | ||||||||
| 資產報廢不再使用 | ||||||||
| 可供交易的證券的未實現收益/(損失) | ( | ) | ||||||
| 存貨損失準備 | ||||||||
| 變動情況： | ||||||||
| 應收補助款 | ||||||||
| 存貨 | ( | ) | ( | ) | ||||
| 應收帳款 | ( | ) | ( | ) | ||||
| 其他流動資產及預付費用 | ||||||||
| 應付帳款 | ( | ) | ||||||
| 應計費用 | ( | ) | ( | ) | ||||
| 營運 租賃負債 | ( | ) | ( | ) | ||||
| 營運活動中使用的淨現金 | $ | ( | ) | $ | ( | ) | ||
| 從投資活動中的現金流量 | ||||||||
| 購買有價證券 | ( | ) | ( | ) | ||||
| 出售有價證券的收益 | ||||||||
| 發行/退回安防存款 | ||||||||
| 購買固定資產 | ( | ) | ( | ) | ||||
| 投資活動提供的凈現金 | $ | $ | ( | ) | ||||
| 來自融資活動的現金流量 | ||||||||
| 通過在市場發行普通股獲得的款項 | ||||||||
| 普通股認股權證的發行 | ||||||||
| 通過證券購買協議II發行普通股和預資融通權證 | ||||||||
| 貸款款項 | ||||||||
| 償還貸款 | ( | ) | ( | ) | ||||
| 融資活動提供的凈現金 | $ | $ | ||||||
| 匯率變動對現金及現金等價物的影響 | ( | ) | ( | ) | ||||
| 現金、現金等價物及限制性現金之增加/(減少) | $ | $ | ( | ) | ||||
| 期初的現金、現金等價物及限制性現金 | ||||||||
| 期末的現金、現金等價物及限制性現金 | $ | $ | ||||||
| 非現金投資和融資活動的補充披露 | ||||||||
| 債務折扣 | $ | $ | ||||||
| 到期貸款負債 | $ | ( | ) | $ | ( | ) | ||
| 認股權負債 | $ | ( | ) | $ | ( | ) | ||
| 衍生負債 | $ | ( | ) | $ | ( | ) | ||
| 租賃資產 | $ | ( | ) | $ | ||||
| 營業租賃負債 | $ | ( | ) | $ | ||||
| 作為證券購買協議II的一部分應收現金 | $ | $ | ||||||
| 現金流項目的補充披露: | ||||||||
| 支付利息 | $ | $ | ||||||
| 所得稅已支付金額 | $ | $ | ||||||
附註是這些未經審計的簡明綜合財務報表的組成部分。
| 8 |
BEYOND AIR，INC.以及其子公司
基本報表附註（未經審計）
注意 1 組織和業務
Beyond Air, Inc.（連同其子公司，「Beyond Air」或「公司」）於2015年4月28日在特拉華州法下成立。2019年6月25日，公司名稱由AIt Therapeutics, Inc.更改爲Beyond Air, Inc.
這個 公司是一家處於商業階段的醫療器械和生物製藥公司，正在開發一氧化氮（「NO」）發生器平台 和交付系統（「LungFit」）® 平台”）能夠從環境空氣中產生 NO。該公司的 第一臺設備，LungFit® PH（“LungFit® PH”) 已獲得上市前批准 (「PMA」) 2022年6月的美國食品藥品監督管理局（「FDA」）。LungFit® PH 系統產生的 NO 顯示爲 改善氧合，減少短期和近期（妊娠期 >34 周）新生兒對體外膜氧合的需求 伴有缺氧呼吸衰竭伴有肺動脈高壓的臨床或超聲心動圖證據 通氣支持和其他適當的藥物。這種情況通常被稱爲持續性肺動脈高壓 新生兒（「PPHN」）。LungFit® 平台最多可以生成百萬分之400（「ppm」）的 NO 直接或通過呼吸機輸送到患者的肺部。LungFit® 可以連續或連續交付 NO 不同流速下的固定時間，能夠按需滴定劑量或保持恒定劑量。在七月 2022年，公司開始營銷 LungFit® 作爲醫療器械的PPHN在美國的PH。
LungFit® 可用於治療使用需要 NO 的呼吸機的患者，以及慢性或急性嚴重肺部感染的患者 通過呼吸面罩或類似設備輸送。此外，該公司認爲還有大量未得到滿足的醫療需求 對於患有某些嚴重肺部感染的患者，LungFit® 平台可能會解決。該公司的 LungFit 的其他重點領域® PPHN 之外的平台是病毒性社區獲得性肺炎（「VCAP」） 包括 COVID-19、細支氣管炎（「BRO」）、非結核分枝桿菌（「NTM」）肺部感染以及肺部感染者 伴有潛在慢性阻塞性肺病（「COPD」）的各種嚴重肺部感染。
在 beyond air 對一氧化氮及其對人類控件的影響的關注下，公司還有兩個不使用的其他項目 LungFit® 通過公司控股的子公司beyond cancer, ltd.（「beyond cancer」） 一氧化氮用於靶向實體腫瘤。LungFit® 平台未被用於實體瘤指徵，因爲需要 超高濃度的氣態一氧化氮（「UNO」）。已經開發出一種專有的遞送系統，旨在 安全地將超過10,000 ppm的UNO直接輸送到實體腫瘤。該項目已進入1期人類臨床試驗。
在2021年11月4日，beyond air將其腫瘤業務重組爲一家名爲Beyond Cancer的新私人公司。beyond air的前臨床腫瘤團隊以及利用UNO治療實體腫瘤的知識產權組合的獨佔權現在歸屬於Beyond Cancer。beyond air擁有
未利用LungFit®平台的第二個項目在大腦中部分抑制神經一氧化氮合酶（nNOS） 以治療神經疾病。第一個目標適應症是自閉症譜系障礙（「ASD」）。2023年6月15日， 公司宣佈已與耶路撒冷希衆研發公司（簡稱大學）達成協議，收購正在開發用於治療ASD和 其他神經疾病的nNOS抑制劑的商業權。目前，尚無FDA批准的專門用於治療ASD的療法。根據協議的條款， beyond air將在協議簽署之日起三年內向大學支付用於臨床前工作的款項。此外， 公司將根據淨銷售額支付低個位數的單次版稅，並基於臨床、監管和銷售里程碑支付某些一次性款項。公司預計 該項目將從臨床前進展到2025年底首次進入人體的一期臨床試驗。
The Company’s current product candidates will be subject to premarket reviews and approvals by the FDA, certification through the conduct of a conformity assessment by a notified body in the European Union (the “EU”), as well as comparable foreign regulatory authorities’ reviews or approvals in other countries or regions.
| 9 |
BEYOND AIR, INC. AND ITS SUBSIDIARIES
基本報表附註（未經審計）
注2 重要的會計政策及其他風險與不確定性
表述基礎
未經審計的簡明綜合財務報表是根據美國通用會計準則（「U.S. GAAP」）和第10-Q表格的說明編制的臨時財務信息。因此，它們不包括所有需要呈現完整財務報表所需的信息和腳註。附表的未經審計的簡明綜合財務報表反映了管理層認爲對所呈現的中期期間結果進行公平呈現必要的所有調整（僅包括正常出現的項目）。截至2024年9月30日的附表未經審計的簡明綜合資產負債表是從公司於2024年3月31日結束的年度報告（即「2024年年度報告」）中的經審計綜合財務報表中獲得的，該報告已於2024年6月24日向美國證券交易委員會（「SEC」）提交。應當結合公司的經審計綜合財務報表及相關附註以及2024年年度報告中的相關附註閱讀附表的未經審計的簡明綜合財務報表和相關披露。
原則 整合的
這些
未經審計的簡明合併基本報表包括公司的賬目以及所有公司的
子公司和一個變量利益實體（「VIE」），公司是主要受益人。由於公司擁有
指導Beyond Cancer活動的權力，這些活動對Beyond Cancer的經濟表現影響最大，並且有權利獲得可能顯著的收益和損失，因此這些基本報表與公司的報表完全合併。非控制性所有者的
重新分類
某些
以前期間的金額已被重新分類，以符合當前期間的表述。在截至2023年9月30日的未經審計的壓縮合並現金流量表中，原先記錄的限制現金金額爲$
使用估計值
根據美國通用會計原則（「U.S. GAAP」）編制基本報表需要管理層做出影響資產和負債報告金額以及在基本報表日期披露或有資產和負債的估計和假設，並會影響報告期的收入和費用的報告金額。 實際結果可能與這些估計有顯著差異。公司持續評估其重要的估計和假設，包括諮詢和臨床試驗協議下的費用確認和應計假設、基於股票的補償、減值評估、對技術使用授權的會計處理及其他開多資產的會計處理、或有事項的確認和應計，以及對遞延稅屬性的估值準備要求的確定。
| 10 |
超越 AIR, INC. 及其子公司
基本報表附註（未經審計）
注意 2 重要會計政策和其他風險與不確定性（繼續）
流動性和其他不確定性
公司在截至2024年9月30日的六個月內的經營活動中使用了現金$
管理層相信，儘管不能保證，但他們已實施的增加收入和減少支出的努力將使公司能夠履行其義務。
公司未來的資金需求和其現有資金的充足性將取決於許多因素，包括但不限於公司批准產品的商業化成功和成本以及當前和預期臨床前研究、臨床試驗和其他必要行動所需的成本和時間，以獲得公司產品候選人的認證或監管批准。
在2024年9月27日，beyond air與包括首席執行官Steven Lisi和董事Robert Carey在內的某些貸款人達成了一個具有約束力的條款清單，關於一筆擔保貸款。該條款清單經過公司的每位獨立和沒有利益衝突的董事的批准，並在收到一家獨立投資銀行的推薦後，該條款清單提供了以下預期條款：
在2024年9月26日，公司與一些機構和認可投資者，包括公司的某些董事和高級職員，簽署了一項證券購買協議（「證券購買協議II」）。根據購買協議，公司向投資者通過定向增發出售了總計的
普通股的分享”，購買價格爲$
每股，(ii) 預先資金的warrants，可購買多達 每股普通股的購買價格爲美元 每個預先資金的warrant和(iii) warrants，可購買多達 普通股的分享，總體毛收益爲$
In
addition, Beyond Air and Avenue Capital Management II, L.P., Avenue Venture Opportunities Fund, L.P. and Avenue Venture
Opportunities Fund II, L.P. (“collectively, Avenue Capital”) reached an agreement to extinguish the Avenue Capital
senior secured term loan for a one-time payment of $
With respect to Beyond Cancer, discussions are underway with investment banks to raise capital based on their most recent top line data from the phase 1a, first-in-human trial which was successful in the first 6 patients with no dose limiting toxicities at the first dose. A combination study with anti-PD1 therapy is expected to begin before the end of calendar 2024 if the company is successful in raising capital.
| 11 |
BEYOND AIR, INC. AND ITS SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE 2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)
Other Risks and Uncertainties
The Company is subject to risks common to development and early-stage medical device companies including, but not limited to, new technological innovations, certifications or regulatory approval, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market acceptance of approved products and the potential need to obtain additional financing. The Company is also dependent on third-party suppliers and, in some cases, single-source suppliers.
The Company’s products require approval or clearance from the FDA prior to commencement of commercial sales in the United States. There can be no assurance that the Company’s products beyond LungFit® PH in the U.S. will receive the required approvals or clearances. Certifications, approvals or clearances are also required in foreign jurisdictions in which the Company may license or sell its products. If the Company is denied such certifications or approvals or clearances or such certifications, approvals or clearances are delayed, such denial or delay may have a material adverse impact on the Company’s results of operations, financial position and liquidity. Further, there can be no assurance that the Company’s product will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed, if at all.
Lease Revenue Recognition
The Company generates revenue from the leases of its LungFit® PH devices to its customers under fixed fee arrangements over periods of up to three years. The fixed fee is typically broken down into ratable monthly payments over the term of the arrangement. The Company’s customers include hospitals and medical facilities. The Company’s LungFit® PH leases include filters, calibration gas, bagging kits, cables, adapters, and other components and accessories required to use the LungFit® PH device (the “Consumables”). The Consumables’ quantities are varied and may be supplied upon demand of the customers and are unlimited, or the arrangement may provide for the maximum quantities available to the customer over the term of the arrangement. The Company’s LungFit® PH leases also include maintenance and training required to use the LungFit® PH device, as well as device back-up services (the “Services”), which are recorded in cost of revenue.
The
Company accounts for its rental arrangements of LungFit® PH devices in accordance with Accounting Standards Codification 842, Leases
(“ASC 842”). Under ASC 842, leases may be classified as either financing, sales-type, or operating, and the Company is required
to disclose key information about leasing arrangements. The classification determines the pattern of revenue recognition and classification
within the statement of operations and comprehensive loss. The Company typically classifies the rental arrangement of its LungFit®
PH contracts as operating leases. The Company’s leases do not contain any restrictive covenants or any material residual value
guarantees. The Company’s equipment leases may contain renewal options which range from
The Company elected the practical expedient applied to operating leases not to separate lease and non-lease components as long as the lease and at non-lease components have the same timing and pattern of transfer. As such, the non-lease components, including the Consumables and Services, are combined with the predominant lease component. The total fixed fees that the Company is reasonably certain to collect are recognized on a straight line basis over the term of the arrangement. Additionally, the Company made an accounting policy election to present LungFit® PH revenue net of sales and other similar taxes.
Amounts billed in advance of performance obligations being satisfied are recognized as deferred revenue.
在租賃開始日，公司將推遲初始直接費用，包括佣金支出，費用將在租賃期限內按照與租賃收入相同的基礎進行確認。
公司在其合併利潤表中將與合同設備和耗材有關的運輸成本記錄在營業收入成本中。
請參閱 未經審計的簡縮合並基本報表第12條，以獲取有關租賃安排的更多信息。
公允價值衡量
截至2024年9月30日和2024年3月31日，公司的金融工具包括受限現金、可市場交易證券、應付賬款、長期負債和歸類爲warrants的債務。此外，截至2024年3月31日，公司的金融工具還包括衍生負債。由於這些帳戶的短期性質，附屬的合併財務報表中報告的現金及現金等價物、受限現金和可市場交易證券的賬面價值近似其各自的公允價值。公司長期負債的賬面價值近似於基於類似借款的當前利率的公允價值，並處於公允價值層次結構的第3級。歸類爲warrants和衍生負債各自以其公允價值計量，並處於公允價值層次結構的第3級。
| 12 |
BEYOND AIR，INC.以及其子公司
基本報表附註（未經審計）
注意 2 重要會計政策和其他風險和不確定性（續）
下表列出了根據ASC 820要求的公允價值層級的每個級別，公司按公允價值定期計量的資產和負債：
截至2024年9月30日的公允價值金額爲：
| (以千爲單位) | 總計 | 等級 1 | 等級 2 | 等級 3 | ||||||||||||
| 有市場的證券： | ||||||||||||||||
| 企業債務證券 | $ | $ | $ | $ | ||||||||||||
| 政府證券 | ||||||||||||||||
| 所有基金類型 | ||||||||||||||||
| 總資產按公允價值測量和記錄 | $ | $ | $ | $ | ||||||||||||
| 負債： | ||||||||||||||||
| 認股權責任 | $ | $ | $ | $ | ||||||||||||
| 衍生負債 | ||||||||||||||||
| 總負債按公允價值測量和記錄 | $ | $ | $ | $ | ||||||||||||
截至2024年3月31日的公允價值金額爲：
| (以千爲單位) | 總計 | 等級 1 | 等級 2 | 等級 3 | ||||||||||||
| 有市場的證券： | ||||||||||||||||
| 企業債務證券 | $ | $ | $ | $ | ||||||||||||
| 政府 證券 | ||||||||||||||||
| 所有基金類型 | ||||||||||||||||
| 總資產按公允價值計量和記錄 | $ | $ | $ | $ | ||||||||||||
| 負債： | ||||||||||||||||
| 認股權責任 | $ | $ | $ | $ | ||||||||||||
| 衍生負債 | ||||||||||||||||
| 總負債按公允價值計量 和記錄 | $ | $ | $ | $ | ||||||||||||
等級 3 估值
在2023年6月與貸款和安防-半導體協議相關發行的普通股warrants（注11）被記錄爲warrant負債， 在截至2024年9月30日的未經審計的合併資產負債表中，因爲這些warrants包含某些結算功能， 而這些功能並未與公司的自身股票掛鉤。此外，長期債務中嵌入的轉換功能要求進行分拆， 因爲對轉換價格的某些調整並未與公司的自身股票掛鉤，因此被記錄爲衍生負債。warrants和衍生負債在每個報告期重新計量，公平價值的變化被記錄爲其他 收入（費用）在合併經營和全面損失的簡表中，直到warrants和衍生品被行使、到期、重新分類或以其他方式結算。用於評估warrants和衍生品的主要假設如下：
| 截至2024年9月30日 | 認購權證 | 衍生品 | ||||||
| 預期期限（以年爲單位） | ||||||||
| 波動率 | % | |||||||
| 無風險利率 | % | |||||||
| 截至2024年3月31日 | 認購權證 | 衍生品 | ||||||
| 預期期限（以年爲單位） | ||||||||
| 波動率 | % | % | ||||||
| 無風險利率 | % | % | ||||||
在2024年9月30日，分拆的衍生責任被重新評估爲零，因爲轉換特徵具有
在2024年9月27日，公司收到了$xx百萬作爲貸款和安全協議的預付款（見註釋14）。作爲貸款和安全協議的一部分，公司發行了給貸款人的認股權證（見註釋13）。
| 截至2024年9月30日 | 認購權證 | |||
| 預期期限（以年爲單位） | ||||
| 波動率 | % | |||
| 無風險利率 | % | |||
| 13 |
BEYOND AIR，INC.以及其子公司
基本報表附註（未經審計）
注意 2 重要會計政策和其他風險和不確定性（續）
下表是截至2024年9月30日的六個月內，公司三級評估的權證和衍生工具公允價值變化摘要（單位：千美元）：
| 認購權證 | 衍生品 | |||||||
| 2024年3月31日結存餘額 | $ | $ | ||||||
| 股份發行 | ||||||||
| 公允價值變動 | ( | ) | ( | ) | ||||
| 2024年9月30日的結餘 | $ | $ | ||||||
下表是截至2023年9月30日，公司對於warrants和衍生工具的第3等級公允價值變動的總結（以千爲單位）：
| 認購權證 | 衍生品 | |||||||
| 股份發行 | $ | $ | ||||||
| 公允價值變動 | ( | ) | ( | ) | ||||
| 2023年9月30日的餘額 | $ | $ | ||||||
現金及現金等價物、短期投資和受限制的現金
本公司將所有原始到期日爲三個月或更短時間的高度流動性投資，以及對美國政府貨幣型基金的投資視爲現金等價物。公司在澳洲、以色列、愛爾蘭和美國的高評級金融機構中維護其現金及現金等價物，這些餘額在某些時候可能超過聯邦保險限額。可交易證券包括對固收債券和美國國債的投資，這些投資被認爲是高度流動且易於交易的。可交易證券被視爲交易證券，按照公允價值計量，並按照ASC 320進行會計處理。可交易證券的估值採用在識別證券的活躍市場中可觀察的輸入，因此在公司的公允價值層級中被歸類爲第一層次。
截至2024年9月30日和2024年3月31日，受限現金約爲$
信貸風險集中
金融
金融工具可能使公司面臨信用風險集中，包括在金融機構中的現金帳戶，這些帳戶在某些時候可能超過聯邦存款保險的覆蓋範圍 $
下表顯示了公司簡明合併現金流量表中現金、現金等價物、有市場流通性的證券按主要安防類型和受限現金的歸納和披露的對賬情況：
| (以千爲單位) | 2024年9月30日 | 三月 2024年31日 | ||||||
| 現金及現金等價物 | $ | $ | ||||||
| 受限現金 | ||||||||
| 現金、現金等價物和受限 現金總計 | $ | $ | ||||||
| 有市場的證券： | ||||||||
| 有價證券 | ||||||||
| 企業債務證券 | $ | $ | ||||||
| 美國政府證券 | ||||||||
| 共同基金（超開空收益） | ||||||||
| 所有基金類型投資 | $ | $ | ||||||
| 總現金、現金及現金等價物、 可交易證券和限制現金 | $ | $ | ||||||
| 14 |
BEYOND AIR，INC.以及其子公司
基本報表附註（未經審計）
注意 2 重要會計政策和其他風險和不確定性（續）
以下表格總結了截至2024年9月30日公司開空市場證券的未實現收益和損失，按主要安防-半導體類型彙總：
| (以千爲單位) | 公平價值 價值 | 未實現 收益 | ||||||
| 企業債務 證券 | $ | $ | ||||||
| 美國政府證券 | ||||||||
| 共同 基金 (超短期收入) | ||||||||
| 總計短期市場可 轉讓證券 | $ | $ | ||||||
以下表格總結了截至2024年3月31日我們開空市場證券的未實現收益和損失，按主要安防-半導體類型彙總：
| (以千爲單位) | 公平價值 價值 | 未實現 盈利和（損失） | ||||||
| 企業債務證券 | $ | $ | ||||||
| 美國政府 證券 | ||||||||
| 共同基金（超短期收入） | ||||||||
| 總短期市場可變證券 | $ | $ | ||||||
所有可市場化證券均爲A-級或更高評級。
板塊報告
自2021年11月創立beyond cancer以來，公司的運營被劃分爲兩個板塊：beyond air和beyond cancer。每個板塊都有自己的管理團隊、董事會、公司高級管理人員和法律實體。截至2024年9月30日，beyond air, inc.擁有
The following table summarizes segment financial information by business segment as of September 30, 2024:
| (in thousands) | Beyond Air | Beyond Cancer | Total | |||||||||
| Cash, cash equivalents, marketable securities and certain restricted cash | $ | $ | $ | |||||||||
| All other assets | ||||||||||||
| Total assets | $ | $ | $ | |||||||||
| Total liabilities | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Net assets | $ | $ | $ | |||||||||
| Non-controlling interests | $ | $ | $ | |||||||||
| 15 |
BEYOND AIR, INC. AND ITS SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE 2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)
The following table summarizes segment financial information by business segment at March 31, 2024:
| (in thousands) | Beyond Air | Beyond Cancer | Total | |||||||||
| Cash, cash equivalents, marketable securities and certain restricted cash | $ | $ | $ | |||||||||
| All other assets | ||||||||||||
| Total assets | $ | $ | $ | |||||||||
| Total liabilities | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Net assets | $ | $ | $ | |||||||||
| Non-controlling interests | $ | $ | $ | |||||||||
The following table summarizes segment financial performance by business segment for the six months ended September 30, 2024:
| (in thousands) | Beyond Air | Beyond Cancer | Total | |||||||||
| Revenue | $ | $ | $ | |||||||||
| Net loss for the six months ended September 30, 2024 | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
The following table summarizes segment financial performance by business segment for the three months ended September 30, 2024:
| (in thousands) | Beyond Air | Beyond Cancer | Total | |||||||||
| Revenue | $ | $ | $ | |||||||||
| Net loss for the three months ended September 30, 2024 | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
The following table summarizes segment financial performance by business segment for the six months ended September 30, 2023:
| (in thousands) | Beyond Air | Beyond Cancer | Total | |||||||||
| Revenue | $ | $ | $ | |||||||||
| Net loss for the six months ended September 30, 2023 | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
The following table summarizes segment financial performance by business segment for the three months ended September 30, 2023:
| (in thousands) | Beyond Air | Beyond Cancer | Total | |||||||||
| Revenue | $ | $ | $ | |||||||||
| Net loss for the three months ended September 30, 2023 | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Research and Development
Research
and development expenses are charged to the unaudited condensed consolidated statements of operations and comprehensive loss as incurred.
Research and development expenses include salaries, benefits, stock-based compensation and costs incurred by outside laboratories, manufacturers,
clinical research organizations, consultants, and accredited facilities in connection with preclinical studies and clinical trials. Research
and development expenses are partially offset by the benefit of tax incentive payments for qualified research and development expenditures
from the Australian tax authority (“AU Tax Rebates”). The Company does not record AU Tax Rebates until payment is received
due to the uncertainty of receipt. In the six months ended September 30, 2024 and September 30, 2023, the Company did
| 16 |
BEYOND AIR, INC. AND ITS SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE 2 SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (continued)
Supplier Concentration
The Company relies on third-party suppliers to provide materials for its devices and consumables.
In
the three months ended September 30, 2024, the Company purchased approximately
In
the six months ended September 30, 2024, the Company purchased approximately
Leases
Operating lease assets are included within operating lease right-of-use assets, and the corresponding operating lease obligation on the consolidated balance sheets as of September 30, 2024 and March 31, 2024 in accordance with ASC 842, Leases. The Company has elected not to present short-term leases as these leases have a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the Company’s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information available at adoption date in determining the present value of lease payments.
NOTE 3 PROPERTY AND EQUIPMENT
Property and equipment consist of the following:
| (in thousands) | September 30, 2024 | March 31, 2024 | ||||||
| Clinical and medical equipment | $ | $ | ||||||
| Equipment deployable as part of a service offering | ||||||||
| Computer equipment | ||||||||
| Furniture and fixtures | ||||||||
| Leasehold improvements | ||||||||
| Accumulated depreciation | ( | ) | ( | ) | ||||
| $ | $ | |||||||
Depreciation
and amortization for the three months ended September 30, 2024 and September 30, 2023 was $
Depreciation
and amortization for the six months ended September 30, 2024 and September 30, 2023 was $
| 17 |
BEYOND AIR, INC. AND ITS SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE 4 STOCKHOLDERS’ EQUITY
On
February 4, 2022, the Company entered into an At-The-Market Equity Offering Sales Agreement with Truist Securities, Inc (the “2022
ATM”), allowing the Company to sell its common stock for aggregate sales proceeds of up to $
During
the six months ended September 30, 2024, the Company received net proceeds of $
On
September 26, 2024, the Company, entered into the Securities Purchase Agreement II with certain institutional and accredited
investors, which included certain directors and officers of the Company, pursuant to which the Company sold, in a private placement
offering, an aggregate of (i) shares
of common stock (ii) pre-funded
stock purchase warrants, (the “Pre-funded Warrants”) to purchase up to
shares of common stock and (iii) stock
purchase warrants (the “Common Warrants” and together with the Pre-funded Warrants, the “Warrants”) to
purchase up to
Pursuant to the Securities Purchase Agreement II, the Company has agreed to use its best efforts to convene an annual or special meeting of its stockholders within 180 days following the Closing Date. At the meeting, the Company’s board of directors will recommend stockholders approve: (i) increasing the number of authorized shares of common stock to ensure the availability of sufficient shares for the full issuance of shares of common stock issuable upon exercise of the outstanding Warrants (the “Authorized Share Proposal”) and (ii) allowing for the exercise price of the Common Warrants to be adjusted in accordance with the terms of the Common Warrants pursuant to the rules and regulations of the Nasdaq Stock Market (the “Warrant Proposal”). The Company will actively solicit proxies from stockholders in support of these proposals, and management-appointed proxyholders will vote their proxies in favor of the proposals. If stockholder approval is not obtained at the initial meeting, the Company will continue to use its best efforts to hold additional meetings every 180 days thereafter to seek stockholders’ approval, until either the approval is obtained or the Common Warrants are no longer outstanding. These warrants cannot be exercised until stockholders approval is obtained.
The
Pre-funded Warrants are exercisable on or after the date on which the Company obtains stockholder approval of the Authorized Share
Proposal (the “Initial Exercise Date”) and shall expire when exercised in full. The Common warrants are not exercisable
until the company obtains shareholder approval at an annual or special meeting of its stockholders to increase the number of
authorized shares of common stock. The Common Warrants are exercisable on or after the Initial Exercise Date (upon shareholder
approval) and will have a term that expires
On
March 20, 2024, the Company, entered into a securities purchase agreement (the “Securities Purchase Agreement”) with
certain institutional and accredited investors, including certain directors and officers of the Company pursuant to which the
Company sold, in a registered direct offering, an aggregate of (i)
shares of common stock and (ii)
common stock purchase warrants to purchase up to
shares of common stock for gross proceeds of $
On
March 20, 2024, the Company also entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital
Partners, LLC and Laidlaw & Company (UK) Ltd. (the “Co-Placement Agents”) as the co-placement agents in connection with
the March 20, 2024 offering. Pursuant to the terms of the Placement Agency Agreement, the Co-Placement Agents agreed to use their reasonable
best efforts to arrange for the sale of the securities in the offering. As compensation to the Co-Placement Agents, the Company paid
the Co-Placement Agents a cash fee of
Stock Option Plans
The Company’s Sixth Amended and Restated 2013 Beyond Air Equity Incentive Plan (the “2013 BA Plan”) allows for awards to officers, directors, employees, and consultants of stock options, restricted stock units and restricted shares of the Company’s common stock. On January 10, 2024, the Company’s Board of Directors approved an amendment to the 2013 BA Plan to increase the number of shares in the 2013 BA Plan by , which was approved by the Company’s stockholders at the 2024 annual stockholder meeting on March 8, 2024. The 2013 BA Plan has shares authorized for issuance. As of September 30, 2024, shares were available under the 2013 BA Plan.
| 18 |
BEYOND AIR, INC. AND ITS SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE 4 STOCKHOLDERS’ EQUITY (continued)
Restricted Stock Units
The fair value for the restricted stock unit awards was valued at the closing price of the Company’s common stock on the date of grant. Restricted stock units vest annually over five years.
A summary of the Company’s restricted stock unit awards for the six months ended September 30, 2024 is as follows:
Number Of Shares | Weighted Average Grant Date Fair Value | |||||||
| Unvested as of April 1, 2024 | $ | |||||||
| Granted | ||||||||
| Vested | ||||||||
| Forfeited | ( | ) | ||||||
| Unvested as of September 30, 2024 | $ | |||||||
Stock-based compensation expense related to these stock issuances for the three months ended September 30, 2024 and September 30, 2023 was $ million and $ million respectively.
Stock-based compensation expense related to these stock issuances for the six months ended September 30, 2024 and September 30, 2023 was $million and $million respectively. The unrecognized compensation cost is $million and the weighted average remaining service period is years.
Number of Options | Weighted Average Exercise Price of Options | Weighted Average Remaining Contractual Life of Options | Aggregate Intrinsic Value (in thousands) | |||||||||||||
| Options outstanding as of April 1, 2024 | $ | $ | | |||||||||||||
| Granted | - | |||||||||||||||
| Exercised | - | |||||||||||||||
| Forfeited | ( | ) | - | |||||||||||||
| Outstanding as of September 30, 2024 | $ | $ | ||||||||||||||
| Exercisable as of September 30, 2024 | $ | $ | ||||||||||||||
The Company’s 2021 Beyond Cancer Ltd Equity Incentive Plan (the “2021 BC Plan”) allows for awards to officers, directors, employees, and consultants of stock options, restricted stock units and restricted shares of Beyond Cancer’s common shares. On November 3, 2022, the Company’s Board of Directors approved an amendment to reserve for issuance an additional shares of common stock. The 2021 BC Plan has shares authorized for issuance. As of September 30, 2024, common shares were available under the 2021 BC Plan.
Number of Options | Weighted Average Exercise Price of Options | Weighted Average Remaining Contractual Life of Options | Aggregate Intrinsic Value (thousands) | |||||||||||||
| Options outstanding as of April 1, 2024 | $ | $ | ||||||||||||||
| Granted | - | |||||||||||||||
| Exercised | - | |||||||||||||||
| Forfeited | ( | ) | - | |||||||||||||
| Outstanding as of September 30, 2024 | $ | $ | ||||||||||||||
| Exercisable as of September 30, 2024 | $ | $ | ||||||||||||||
As of September 30, 2024, the Company had unrecognized stock-based compensation expense in the 2013 BA Plan of approximately $ million which was expected to be expensed over the weighted average remaining service period of years.
As of September 30, 2024, the Company had unrecognized stock-based compensation expense in the 2021 BC Plan of approximately $ million which is expected to be expensed over the weighted average remaining service period of years.
| 19 |
BEYOND AIR, INC. AND ITS SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE 4 STOCKHOLDERS’ EQUITY (continued)
September 30, 2024 | September 30, 2023 | |||||||
| Risk-free interest rate | – | % | – | % | ||||
| Expected volatility (Beyond Air) | – | % | – | % | ||||
| Expected volatility (Beyond Cancer) | - | % | ||||||
| Dividend yield | % | % | ||||||
| Expected terms (in years) | ||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| (in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||
| General and administrative | ||||||||||||||||
| Total stock-based compensation expense | $ | $ | $ | $ | ||||||||||||
Warrants
A summary of the Company’s outstanding warrants as of September 30, 2024 is as follows:
| Warrant Holders | Number of Warrants | Exercise Price | Intrinsic Value (in thousands) | Date of Expiration | ||||||||||
| March 2020 loan | $ | $ | ||||||||||||
| NitricGen agreement | $ | |||||||||||||
| Avenue agreement | $ | |||||||||||||
| March 2024 raise | $ | |||||||||||||
| Avenue extension agreement | $ | |||||||||||||
| September 2024 equity offering | $ | |||||||||||||
| September 2024 debt instrument | $ | |||||||||||||
| Sub-total | $ | $ | ||||||||||||
| Pre-funded warrants | $ | |||||||||||||
| Total | $ | |||||||||||||
On
September 30, 2024, warrants to purchase up to an aggregate of
On September 30, 2024, warrants to purchase up to
On September 30, 2024, warrants to purchase up to
an aggregate of
On
June 21, 2024, warrants to purchase up to an aggregate of
Warrants
to purchase up to
Upon completion of the Securities Purchase Agreement
II and in accordance with their original terms, the
| 20 |
BEYOND AIR, INC. AND ITS SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE 5 OTHER CURRENT ASSETS AND PREPAID EXPENSES
A summary of current assets and prepaid expenses as of September 30, 2024 and March 31, 2024 is as follows (in thousands):
September 30, 2024 | March 31, 2024 | |||||||
| Research and development | $ | $ | ||||||
| Insurance | ||||||||
| Prepaid rents and tenant improvement | ||||||||
| Demonstration materials | ||||||||
| Value added tax receivable | ||||||||
| Cash receivable as part of Securities Purchase Agreement II | ||||||||
| Deposits to secure manufacturing materials | ||||||||
| Other | ||||||||
| Total | $ | $ | ||||||
NOTE 6 ACCRUED EXPENSES
A summary of the accrued expenses as of September 30, 2024 and March 31, 2024 is as follows (in thousands):
September 30, 2024 | March 31, 2024 | |||||||
| Research and development | $ | $ | ||||||
| Professional fees | ||||||||
| Employee salaries and benefits | ||||||||
| Contingent litigation and settlements (Note 10) | ||||||||
| Circassia settlement – current portion (Note 8) | ||||||||
| Deferred revenue | ||||||||
| Goods received not invoiced | ||||||||
| Other | ||||||||
| Total short-term accrued expenses | $ | $ | ||||||
| 21 |
BEYOND AIR, INC. AND ITS SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
The following potentially dilutive securities were not included in the calculation of diluted net income (loss) per share attributable to common stockholders of Beyond Air because their effect would have been anti-dilutive for the periods presented:
September 30, 2024 | September 30, 2023 | |||||||
| Common stock warrants | ||||||||
| Common stock options | ||||||||
| Restricted shares | ||||||||
| Loan and Security – conversion feature | ||||||||
| Total | ||||||||
NOTE 8 CIRCASSIA AGREEMENT
On January 23, 2019, the Company entered into an agreement for commercial rights (the “Circassia Agreement”) with Circassia Limited and its affiliates (collectively, “Circassia”) for PPHN and future related indications at concentrations of < 80 ppm in the hospital setting in the United States and China. On December 18, 2019, the Company terminated the Circassia Agreement.
On
May 25, 2021, the Company and Circassia entered into a settlement agreement (the “Settlement Agreement”) resolving all claims
by and between both parties and mutually terminating the Circassia Agreement. Pursuant to the terms of the Settlement Agreement, the
Company agreed to pay Circassia $
NOTE 9 GRANT COLLABORATION AGREEMENT
On
February 10, 2021, the Company received a grant for up to $
| 22 |
BEYOND AIR, INC. AND ITS SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE 10 COMMITMENTS AND CONTINGENCIES
License Agreements
In
August 2015, Beyond Air Ltd., a wholly-owned subsidiary of the Company (“BA Ltd.”) entered into an Option Agreement (the
“Option Agreement”) with Pulmonox Technologies Corporation (“Pulmonox”) whereby BA Ltd. acquired the option (the
“Option”) to purchase certain intellectual property assets and rights. On January 13, 2017, BA Ltd. exercised the Option
and paid $
On
January 31, 2018, the Company entered into an agreement (the “NitricGen Agreement”) with NitricGen, Inc. (“NitricGen”)
to acquire a global, exclusive, transferable license and associated assets including intellectual property, know-how, trade secrets and
confidential information from NitricGen related to the LungFit®. The Company acquired the licensing right to use the technology
and agreed to pay NitricGen a total of $
Supply Agreement and Purchase Order
In
August 2020, the Company entered into a supply agreement with an initial expiration date of December 31, 2024. The agreement will renew
automatically for successive three-year periods unless and until the Company provides 12 months’ notice of intent not to renew.
As of the date of this report, the Company has not provided such notice. The Company has opened several non-cancellable purchase orders
and the outstanding amount remaining under the purchase order as of September 30, 2024 was approximately $
Contingencies
In
April 2023, the Company paid a total of $
In
December 2021, Hudson Bay Master Fund (“Hudson”) filed a lawsuit in the Supreme Court on the State of New York against the
Company relating to the notice of adjustment of the exercise price of and the number of warrant shares issuable under warrants issued
to Hudson in January 2017. Hudson received
From time to time, we are involved in various legal matters arising in the normal course of business. We do not expect the outcome of such proceedings, either individually or in the aggregate, to have a material effect on our financial position, cash flows or results of operations.
| 23 |
BEYOND AIR, INC. AND ITS SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE 11 LOANS
Loan and Security Agreement
On
June 15, 2023 (the “Closing Date”), Beyond Air, Inc. and its wholly-owned subsidiary, Beyond Air Ltd., entered into a Loan
and Security Agreement (the “Loan and Security Agreement”) with Avenue Capital Management II, L.P., as administrative agent
and collateral agent (the “Agent”) and the Lenders. Also on June 15, 2023, the Company entered into a Supplement to the Loan
and Security Agreement (collectively with the Agreement, the “Loan Agreement”) with the Agent and the Lenders. The Loan Agreement
provides for senior secured term loans (the “Loans”) in an aggregate principal amount up to $
Pursuant
to the Loan Agreement, the Company is subject to a financial covenant requiring the Company to maintain at all times $
| 24 |
BEYOND AIR, INC. AND ITS SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE 11 LOANS (continued)
The
Loan Agreement also includes events of default customary for financings of this type, in certain cases subject to customary periods to
cure, following which the Agent may accelerate all amounts outstanding under the Loans. The Company granted the Lenders warrants to purchase
an aggregate of
The
Company also granted the Lenders conversion rights for up to $
On
June 21, 2024, the Company, in return for extending the interest-only period for an additional 6 months on the Loan and Security Agreement
with Avenue Capital, entered into an agreement to issue warrants to purchase up to
The warrants are freestanding liability classified financial instruments to which a portion of the debt proceeds were allocated to warrants and based on the warrants estimated fair value at issuance. The remaining proceeds were allocated to the long-term debt. Costs allocated to the warrants were expensed immediately and costs allocated to the debt are recorded as a debt discount and are amortized into interest expense over the life of the debt using the effective interest method. The conversion feature was bifurcated from the debt and is accounted for as a derivative liability.
The
agreement contains an end of term liability of $
On
September 30, 2024, Beyond Air and Avenue Capital reached an agreement to extinguish the Avenue Capital senior secured term loan for
a one-time payment of $
| 25 |
BEYOND AIR, INC. AND ITS SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE 11 LOANS (continued)
| Maturity of Long-Term Loan (in thousands) | September 30, | |||
| 2025 | $ | |||
| 2026 | ||||
| 2027 | ||||
| 2028 | ||||
| Total | $ | |||
Components of Loan and Security Agreement
September 30, 2024 | March 31, 2024 | |||||||
| Amount outstanding | $ | $ | ||||||
| Debt discount | ( | ) | ( | ) | ||||
| Amortization of debt discount | ||||||||
| Final payment liability | ||||||||
| Total | $ | $ | ||||||
NOTE 12 – LEASE REVENUES
The
Company leases the LungFit® PH device to customers and receives a fixed rental fee over the term of the arrangement. Contract terms
(generally -to-
The
Company recognized $
The
Company recognized $
| 26 |
BEYOND AIR, INC. AND ITS SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE 12 – LEASE REVENUES (continued)
The following schedule presents the minimum future lease payments under the LungFit® PH lease arrangements that were in place as of September 30, 2024 (in thousands):
| Future lease payments under the LungFit® PH lease arrangements (in thousands) | September 30 | |||
| 2025 | $ | |||
| 2026 | ||||
| 2027 | ||||
| 2028 | ||||
| Total | $ | |||
The
LungFit® PH devices are included in Property and Equipment (Note 3) and have the useful life of
Depreciation
expense related to leased LungFit® PH devices was $
The depreciation expense related to customer leased devices is included in the cost of revenue in the consolidated statements of operations and comprehensive loss.
Capitalized sales commissions
Sales commissions related to obtaining LungFit® PH lease agreements are accounted for as initial direct costs and are capitalized and amortized on a straight-line basis over the lease term. Total capitalized costs for the three and six months ended September 30, 2024 and September 30, 2023 were immaterial.
NOTE 13 – LONG TERM LIABILITIES, RELATED PARTY
| September 30 | ||||
| Advance payment on loan and security agreement | $ | |||
| Debt discount | $ | ( | ) | |
| $ | ||||
On September 27, 2024, the company received $
As
part of the loan and security agreement, the company issued warrants to the lenders. The
| September 30, 2024 | ||||
| Risk-free interest rate | % | |||
| Expected volatility (Beyond Air) | % | |||
| Dividend yield | % | |||
| Expected terms (in years) | ||||
NOTE 14 – SUBSEQUENT EVENTS
On
November 1, 2024, Beyond Air, Inc. (the “Company”) entered into a loan and security agreement (the “loan agreement”)
for a secured loan with certain lenders including its Chief Executive Officer Steven Lisi and director Robert Carey (collectively, the
“Lenders”). The loan agreement was approved by each of the Company’s independent and disinterested directors, following
the receipt of a recommendation from an independent investment bank. The loan agreement provides for the following expected terms:
On
October 4 2024, the sum of $
| 27 |
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q (this “Form 10-Q”) contains “forward-looking statements.” We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts contained in this Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, prospective product candidates and products, product approvals, timing of our clinical development activities, research and development costs, timing and likelihood of success and the plans and objectives of management for future operations and future results of anticipated products are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements express or implied by the forward-looking statements.
In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “expect,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar conditional expressions. The forward-looking statements in this Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Form 10-Q and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described under the sections in this Form 10-Q titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” Item 1A “Risk Factors” contained in our most recently filed Annual Report on Form 10-K, as well as the following:
| ● | our ability to successfully commercialize our LungFit® PH system in the U.S.; | |
| ● | our ability to obtain CE Certificate of Conformity to CE mark LungFit® in the European Union (the “EU”); | |
| ● | our expectation to incur losses for the next few years; | |
| ● | our ability to predict accurately the demand for our products, and products under development and to develop strategies to address markets successfully; | |
| ● | the possibility that products may contain undetected errors or defects or otherwise not perform as anticipated; | |
| ● | the anticipated development of markets we sell our products into and the success of our products in these markets; | |
| ● | our future capital needs and our need to raise additional funds; | |
| ● | our ability to build a pipeline of product candidates and develop and commercialize our approved products; | |
| ● | our ability to enroll patients in clinical trials, timely and successfully complete those trials and receive necessary certifications or regulatory approvals; | |
| ● | our ability to maintain our existing or future collaborations or licenses; | |
| ● | our ability to protect and enforce our intellectual property rights; | |
| ● | Federal, state, and foreign regulatory requirements, including the U.S Food and Drug Administration (“FDA”) regulation of our approved product and product candidates; | |
| ● | our ability to obtain and retain key executives and attract and retain qualified personnel; and | |
| ● | our ability to successfully manage our growth, including as a commercial-stage company. |
Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.
You should read this Form 10-Q and the documents that we reference in this Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Beyond Air, Inc. the Beyond Air logo and other trademarks or service marks of Beyond Air, Inc. appearing in this Form 10-Q are the property of Beyond Air, Inc. This Form 10-Q also includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this Form 10-Q appear without the ® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.
| 28 |
Introduction
We are a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (“NO”) generators and delivery systems (the “LungFit® platform”) capable of generating NO from ambient air. Our first device, LungFit® PH received premarket approval (“PMA”) from the FDA in June 2022. The NO generated by the LungFit® PH system is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. This condition is commonly referred to as persistent pulmonary hypertension of the newborn (“PPHN”). The LungFit® platform can generate NO up to 400 parts per million (“ppm”) for delivery to a patient’s lungs directly or via a ventilator. LungFit® can deliver NO either continuously or for a fixed amount of time at various flow rates and has the ability to either titrate dose on demand or maintain a constant dose. In July 2022, we commenced marketing LungFit® PH in the United States for PPHN as a medical device.
LungFit® can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections via delivery through a breathing mask or similar apparatus. Furthermore, we believe that there is a high unmet medical need for patients suffering from certain severe lung infections that the LungFit® platform can potentially address. Our current areas of focus with LungFit® are PPHN, viral community-acquired pneumonia (“VCAP”) including COVID-19, bronchiolitis (“BRO”), nontuberculous mycobacteria (“NTM”) lung infection and those with various severe lung infections with underlying chronic obstructive pulmonary disease (“COPD”). Our current product candidates will be subject to premarket reviews and approvals by the FDA, certification through the conduct of a conformity assessment by a notified body in the EU for the product to be CE marked, as well as comparable foreign regulatory authorities.
With Beyond Air’s focus on NO and its effect on the human condition, there are two additional programs that do not utilize our LungFit® system. Through our majority-owned affiliate Beyond Cancer, Ltd. (“Beyond Cancer”), NO is used to target solid tumors. The LungFit® platform is not utilized for the solid tumor indication due to the need for ultra-high concentrations of gaseous nitric oxide (“UNO”). A proprietary delivery system has been developed that is designed to safely deliver UNO in excess of 10,000 ppm directly to a solid tumor. This program has advanced to phase 1 clinical trials.
On November 4, 2021, we reorganized our oncology business into a new private company called Beyond Cancer. Our preclinical oncology team and the exclusive right to the intellectual property portfolio utilizing UNO for the treatment of solid tumors now reside with Beyond Cancer. Beyond Air has 80% ownership in Beyond Cancer.
The second program, which does not utilize the LungFit® platform, partially inhibits neuronal nitric oxide synthase (“nNOS”) in the brain to treat neurological conditions. The first target indication is autism spectrum disorder (“ASD”). ASD is a serious neurodevelopmental and behavioral disorder, and one of the most disabling conditions and chronic illnesses in children. ASD includes a wide range of developmental disorders that share a core of neurobehavioral deficits manifested by abnormalities in social interactions, deficits in communication, restricted interests, and repetitive behaviors. In 2023, the CDC reported that approximately 1 in 36 children in the U.S. is diagnosed with an ASD. The cost of caring for Americans with autism had reached $268 billion in 2015 and would rise to $461 billion by 2025 in the absence of more-effective interventions and support across the life span. We expect this program to progress from preclinical to a phase 1 first-in-human clinical trial in 2025. Beyond Air has formed a wholly owned subsidiary called NeuroNOS which is responsible for pre-clinical and clinical development.
LungFit® PH is the first FDA-approved system using our patented plasma pulse technology to generate on-demand NO from ambient air and, regardless of dose or flow, deliver it to a ventilator circuit. The device uses a medical air compressor to drive room air through a plasma chamber in the center of the unit where pulses of electrical discharge are created between two electrodes. The system uses the power equivalent to a 60-watt lightbulb to ionize the nitrogen and oxygen molecules, which then combine as NO with low levels of nitrogen dioxide (“NO2”) created as a byproduct. The products are then passed through a Smart Filter, which removes the toxic NO2 from the internal circuit. With respect to PPHN, the novel LungFit® PH is designed to deliver a dosage of NO to the lungs that is consistent with current guidelines for delivery of 20 ppm NO with a range of 0.5 ppm – 80 ppm (low concentration NO) for ventilated patients.
We believe the ability of LungFit® PH to generate NO from ambient air provides us with many competitive advantages over the current standard of NO delivery systems in the U.S., the EU, Japan and other markets. For example, LungFit® PH does not require the use of a high-pressure cylinder, does not require cumbersome purging procedures and places less burden on hospital staff in carrying out safety procedures.
Our novel LungFit® platform can also deliver a high concentration (>150 ppm) of NO directly to the lungs, which we believe has the potential to eliminate microbial infections including bacteria, fungi and viruses, among others. We believe that current FDA-approved NO vasodilation treatments would have limited success in treating microbial infections given the low concentrations of NO being delivered (<100 ppm). Given that NO is produced naturally by the body as an innate immunity mechanism, at a concentration of 200 ppm, supplemental high dose NO should aid in the body’s fight against infection. Based on our preclinical studies and clinical trials, we believe that 150 ppm is the minimum therapeutic dose to achieve the desired pulmonary antimicrobial effect of NO. To date, neither the FDA nor comparable foreign regulatory agencies in other countries or regions have approved any NO formulation and/or delivery system for >80 ppm NO.
LungFit® PH for the treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN)
In June 2022, the FDA approved LungFit® PH to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. LungFit® PH is the inaugural device from the LungFit® platform of NO generators that use patented ionizer technology and is the first FDA-approved product for Beyond Air.
| 29 |
We submitted a PMA supplement to the FDA in November 2023 for the expansion of the label to include certain cardiac surgeries and we expect to receive CE mark under the Medical Device Regulation (“MDR”) in the EU during the second half of calendar 2024. According to the most recent year-end report from Mallinckrodt Pharmaceuticals (“Mallinckrodt”), sales of NO were $303.2 million in 2023 (down from $339.7 million in 2022) for the United States, Canada, Japan, Mexico and Australia, with >90% in the United States. Outside of the U.S. there are multiple market participants which translates to considerably lower sales than in the U.S. We believe the addressable U.S. market for LungFit® PH to be approximately $350 million and worldwide to be approximately $700 million. We initiated the first phase of our commercial launch (the limited launch phase to introduce Lungfit PH and Beyond Air to hospitals) in July 2022, and entered into phase 2 (to target initial market share gains in certain geographies) with an expanded commercial presence during the spring of 2023 in the U.S. and will continue to work towards a potential launch in the EU and globally in 2024 and beyond. We anticipate entering the final phase of our launch process in calendar 2025 where we intend to equip our commercial organization to become the market leader in the U.S. in a few years.
LungFit® PRO for the treatment of viral lung infections in hospitalized patients
Viral Community-Acquired Pneumonia (including COVID-19)
Viral pneumonia in adults is most commonly caused by rhinovirus, respiratory syncytial virus (“RSV”) and influenza virus. However, newly emerging viruses (including SARS-CoV-1, SARS-CoV-2, avian influenza A, and H1N1 viruses) have been identified as pathogens contributing to the overall burden of adult viral pneumonia. COVID-19 is an infectious disease caused by SARS-CoV-2, that resulted in a global pandemic, causing millions of hospitalizations and over 7 million deaths worldwide reported as of January 2024, according to the World Health Organization. Excluding the pandemic, there are approximately 350,000 annual viral pneumonia hospitalizations in the U.S., and up to 16 million annual viral pneumonia hospitalizations globally. For the broader annual viral pneumonia hospitalizations, we believe U.S. market potential to be greater than $1.5 billion and worldwide market potential to be greater than $3 billion.
We initiated a pilot clinical trial in late 2020 using our novel LungFit® PRO system at 150 ppm to treat patients with VCAP. The trial was a multi-center, open-label, randomized clinical trial in Israel, including patients infected with COVID-19. Patients were randomized in a 1:1 ratio to receive either inhalations of 150 ppm NO given intermittently for 40 minutes four times per day for up to seven days in addition to standard supportive treatment (“NO+SST”) or standard supportive treatment alone (“SST”). Endpoints related to safety (primary endpoint), oxygen saturation and ICU admission, among others, were assessed.
We presented results from the pilot clinical trial at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022), which took place from April 23, 2022 through April 26, 2022 as a hybrid event both onsite in Lisbon, Portugal and online. At the time of the data cut off, the trial enrolled a total of 40 patients hospitalized for VCAP (SARS-CoV-2, n=39; other viruses n=1). The intent-to-treat population included 35 patients with 16 patients in the inhaled NO group and 19 patients in the control group. The primary COVID-19 treatments used during the clinical trial were Remdesivir (>30%) and Dexamethasone (>65%). Safety data from the clinical trial show that inhaled NO treatment was well tolerated overall with no treatment related adverse events as assessed by the investigators. There were two serious adverse events (“SAEs”) reported in the group receiving inhaled NO along with SST, which were determined to be related to underlying conditions and unrelated to clinical trial drug/device. From an efficacy perspective, results show a trend of shortening length of stay (“LOS”) by a factor 1.8 in favor of inhaled NO treatment. Duration of oxygen support, measured in-hospital and at home, was significantly shorter (p=0.0339) for inhaled NO treated patients. Patients with unstable oxygen saturation during hospitalization, 66.7% of the inhaled NO treatment group, reached stable saturation of ≥93% during hospital stay as compared to 26.7% in the SST group.
Following completion of the clinical trial and the 180-day follow-up period, incremental data were provided in a poster presentation at IDWeek 2022 held from October 19, 2022, through October 23, 2022 in Washington, D.C. In addition to the positive clinical results provided at ECCMID 2022, the poster showed a larger decline in c-reactive protein (“CRP”) from baseline for patients treated with NO + SST compared to the control group. Analysis of the data provides compelling evidence that high concentration NO delivery with the LungFit® PRO generator and delivery system can be a powerful tool against any type of pneumonia, especially COVID-19. The Company commenced a clinical trial in the second half of calendar 2023 in the United States and has made the decision to pause this study pending future funding.
Bronchiolitis (BRO)
Bronchiolitis is the leading cause of hospital admission in children less than 1 year of age. The incidence is estimated to be 150 million new cases a year worldwide, with 2-3% (over 3 million) of them severe enough to require hospitalization. Worldwide, 95% of all cases occur in developing countries. In the U.S., there are approximately 120,000 annual bronchiolitis hospitalizations and approximately 3.2 million annual child hospitalizations globally. Currently, there is no approved treatment for bronchiolitis. The treatment for acute viral lung infections that cause bronchiolitis in infants is largely supportive care and is based primarily on prolonged hospitalization during which the infant receives a constant flow of oxygen to treat hypoxemia, a reduced concentration of oxygen in the blood. In addition, systemic steroids and inhalation with bronchodilators are sometimes utilized until recovery, but we believe that these treatments do not successfully reduce hospital LOS. We believe the U.S. market potential for bronchiolitis to be greater than $500 million and worldwide market potential to be greater than $1.2 billion.
The pivotal clinical trial for bronchiolitis was originally set to be performed in the winter of 2020/21 but was delayed due to the pandemic. We have completed three successful pilot studies for bronchiolitis. A further analysis of the three previously reported pilot studies was presented at the ATS International Conference 2021, which was held virtually from May 14, 2021 through May 19, 2021. Analysis across the studies (n=198 infants, mean age 3.9 months) showed that 150 ppm – 160 ppm NO administered intermittently was generally safe and well tolerated with adverse event rates similar among treatment groups with no reported treatment-related serious adverse events. The short course of treatments with intermittent high concentration inhaled NO was effective in shortening hospital LOS and accelerating time to fit for discharge – a composite endpoint of clinical signs and symptoms to indicate readiness to be evaluated for hospital discharge. This treatment was also effective in accelerating time to stable oxygen saturation – measured as SpO2 ≥ 92% in room air. Additionally, NO at a dose of 85 ppm NO showed no difference compared to control for all efficacy endpoints, while 150 ppm NO showed statistical significance when compared to control.
| 30 |
Additionally, long-term safety data for high concentration inhaled NO in bronchiolitis was presented at the Pediatric Academic Societies Meeting 2022 (PAS 22), which was held in Denver, Colorado from April 21, 2022 through April 25, 2022. A total of 101 infants from the three prior pilot studies for bronchiolitis (n=198) participated in the long-term follow-up clinical trial. Clinical trial endpoints for the long-term safety clinical trial included percentage of patients re-hospitalized for bronchiolitis related reasons, such reasons included wheezing episodes, pneumonia, and asthma and the percentage of patients re-hospitalized for any reason. Data from the clinical trial showed the re-hospitalization rate per 100 Patient Exposure Years (PEY) due to bronchiolitis related reasons trended favorably for the inhaled NO group. In addition, the long-term patient re-hospitalization rate for any reason was similar between inhaled NO and control groups. As such, the clinical trial concluded that the treatment of hospitalized infants with acute bronchiolitis by intermittent high dose inhaled NO shows a favorable long-term safety profile.
We believe that the entirety of data at 150 ppm – 160 ppm NO in both adult and infant patient populations supports further development of LungFit® PRO in a pivotal clinical trial for patients hospitalized with VCAP or bronchiolitis.
LungFit® GO for the treatment of Nontuberculous mycobacteria (NTM)
NTM lung infection is a rare and serious pulmonary disease associated with increased morbidity and mortality. Patients with NTM lung disease may experience a multitude of symptoms such as fever, weight loss, cough, lack of appetite, night sweats, blood in the sputum and fatigue. Patients with NTM lung disease, specifically Mycobacterium abscessus (M. abscessus) representing 20% to 25% of all NTM and other forms of NTM that are refractory to antibiotic therapy, frequently require lengthy and repeated hospital stays to manage their condition. There are no treatments specifically indicated for the treatment of M. Abscessus lung disease in North America, Europe or Japan.
Current estimates place the number of people with NTM infections in the U.S as high as 220,000. It is estimated that in Asia, the number of patients suffering from NTM surpasses what is seen in the U.S. There is one inhaled antibiotic approved for the treatment of refractory Mycobacterium avium complex (“MAC”). Current guideline-based approaches to treat NTM lung disease involve multi-drug regimens of antibiotics that may cause severe, long lasting side effects, and treatment can be longer than 18 months. Median survival for NTM MAC patients is approximately 13 years while median survival for patients with other variations of NTM is typically 4.6 years. The prevalence of human disease attributable to NTM has increased over the past two decades. In a clinical trial conducted between 2007 and 2016, researchers found that the prevalence of NTM in the U.S. is increasing at approximately 7.5% per year. M. abscessus treatment costs are estimated to be more than double that of MAC. A 2015 publication by co-authors from several U.S. government departments stated that cases in 2014 alone cost the U.S. healthcare system approximately $1.7 billion. For this indication, we believe U.S. sales potential to be greater than $1 billion and worldwide sales potential to be greater than $2.5 billion.
In December 2020 we began a 12-week, multi-center, open-label clinical trial in Australia intended to enroll approximately 20 adult patients with chronic refractory NTM lung disease. We received a grant of up to $2.17 million from the Cystic Fibrosis Foundation (“CFF”) to fund this clinical trial and advance the clinical development of inhaled NO to treat NTM pulmonary disease. The trial enrolled both cystic fibrosis (“CF”) and non-CF patients infected with MAC, M. abscessus or any strain of NTM. The clinical trial consisted of a run-in period followed by two treatment phases. The run-in period provided a baseline for the efficacy endpoints. The first treatment phase took place over a two-week period and began in the hospital setting where patients were titrated from 150 ppm NO up to 250 ppm NO over several days. During this phase patients received NO for 40 minutes, four times per day while Methemoglobin (“MetHb”) levels were monitored. Patients were also trained to use LungFit® GO and subsequently discharged to complete the remaining portion of the two-week treatment period at their home at the highest tolerated NO concentration. For the second treatment phase, a 10-week maintenance phase, the administration was twice daily. The clinical trial evaluated safety, quality of life, physical function, and bacterial load among other parameters.
At the American Thoracic Society International Conference 2022 (ATS 2022), which was held in San Francisco from May 13, 2022 through May 18, 2022, we presented positive interim data from the ongoing clinical trial. At the time of data cutoff on April 4, 2022, a total of 15 patients were enrolled in the pilot clinical trial. The mean age of patients was 62.1 years (range: 22 – 82 years) with the majority female (80%), a distribution consistent with real-world NTM disease. All 15 patients were successfully titrated to 250 ppm NO in the hospital setting, and no patients required dose reductions during the subsequent at-home portion of the clinical trial. Patients were followed up for 12 weeks after the 12-week treatment period was completed.
After completion of the clinical trial, we presented positive results at the American College of Chest Physicians (“CHEST”) annual meeting, held from October 16, 2022 through October 19, 2022, further supporting development of intermittent high dose NO for the treatment of NTM. The clinical trial demonstrated that high dose NO treatment was well-tolerated in both the home and hospital settings. During the 10-week at-home treatment period of the clinical trial, a total of 2,492 inhalations were self-administered with overall high treatment compliance (>90%). There were no SAEs related to treatment discontinuations reported over the 12-week treatment or 12-week follow up periods. Key efficacy endpoints showed strong results with improvement seen in the majority of quality-of-life domains. Respiratory function and physical function were maintained during treatment and follow-up. Trends in the reduction of microbial load were observed and one patient achieved culture conversion with three consecutive negative sputum samples. We anticipate commencing a pivotal clinical trial in calendar year 2026 following discussions with the FDA.
Our program in COPD is in the preclinical stage and will move forward subject to obtaining additional financing.
| 31 |
Ultra-High Concentration NO (UNO) in solid tumors through majority-owned affiliate Beyond Cancer, Ltd.
In the fourth calendar quarter of 2021, Beyond Cancer, our majority-owned affiliate, raised $30 million in a private placement of common shares. The investors purchased a 20% equity ownership in Beyond Cancer, while Beyond Air maintained 80% equity ownership. The funding is being used to accelerate ongoing preclinical work, including the completion of IND-enabling studies, completion of a Phase 1 clinical trial, expansion of preclinical programs for combination studies, hiring of additional Beyond Cancer team members, and optimization of the delivery system, as well as for general corporate purposes.
Beyond Cancer will benefit from Beyond Air’s NO expertise, IP portfolio, preclinical oncology team, and regulatory progress, and will pay Beyond Air a single-digit royalty on all future revenues. Beyond Cancer is being led by a seasoned leadership team with experience in emerging healthcare companies and clinical oncology.
UNO has shown anticancer properties in preclinical trials by eliciting an immune response from the host. We have released preclinical data at several medical/scientific conferences showing the promise of delivering NO directly to tumors at concentrations of 20,000 ppm – 200,000 ppm. Results showed that local tumor ablation with NO conveyed anti-tumor immunity to the host. In April 2022, we presented in vivo and in vitro preclinical data at the American Association for Cancer Research (“AACR”) 2022 annual meeting. The in vivo study assessed the mode of action following a single 5-minute gaseous NO (“gNO”) treatment which provided data showing an effect on the primary tumor 14 days post-treatment. These data showed that intratumoral injections of concentrations of gNO at 20,000 and 50,000 ppm led to increased recruitment of T cells, B cells, macrophages, and dendrocytes to the primary tumor. An elevated number of T cells and B cells were also detected in the spleen and blood 21 days following gNO treatment. In addition, at the same time point, a marked reduction in the number of myeloid-derived suppressor cells was observed in the spleen. Results from the in vitro study showed that exposure of six different cancer cell lines – including human ovarian and pancreatic and mouse lung, melanoma, colon, and breast – to UNO ranging from 10,000 ppm to 100,000 ppm for up to 10 minutes resulted in a dose-dependent cytotoxic response. The higher concentration doses of gNO led to near-instant cell death, while the lower concentration doses required a longer exposure period to elicit cell death. Cell viability was assessed using two assays: XTT and clonogenic assay. After one minute of exposure to 25,000 ppm gNO, less than 10% viability was observed in all cell lines.
The second half of calendar year 2022 was a time of significant progress for Beyond Cancer. On August 23, 2022, we announced that the first patient was treated in a first-in-human Phase 1 clinical trial to assess the safety and immune biomarkers of UNO therapy. In November, at the annual meeting of the Society for Immunotherapy of Cancer (“SITC”), we presented new in vivo combination data that support the potential of our novel UNO therapy to treat various types of solid tumors in combination with immune checkpoint inhibitor (“ICI”) therapies, including anti-PD-1. The data presented at SITC appears to indicate that UNO in combination with anti-PD-1 treatment may lead to higher tumor regression rates and prolonged survival. Also in 2022, on December 13, we announced the publication of preclinical data in the peer-reviewed journal Cancer Cell International (CCI), which showed that our proprietary tumor ablation technology utilizing UNO induced a potent innate and adaptive immune response that prevented metastases and resulted in a statistically significant survival benefit.
Calendar year 2023 began with the announcement of Beyond Cancer’s entry into a sponsored research agreement with Stanford School of Medicine and the appointment of Frederick M. Dirbas, MD, Associate Professor of Surgery, Division of Surgical Oncology, Stanford School of Medicine, and Mark D. Pegram, MD, the Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology at the Stanford School of Medicine, to the Beyond Cancer Scientific Advisory Board (“SAB”). In addition to the research agreement, Dr. Dirbas was named as Chair of the SAB, which provides guidance for ongoing preclinical studies as well as ongoing and planned future clinical trials in the use of UNO to treat solid tumors. The newly appointed members of the SAB will work to provide input on the clinical development of Beyond Cancer’s UNO technology, particularly as it relates to the U.S. regulatory submission.
In April 2023, Beyond Cancer presented additional preclinical data for UNO therapy in solid tumors during the AACR 2023 annual meeting. Data showed a statistically significant survival benefit for repeat dosing of UNO compared to anti-mCTLA-4 as monotherapy and repeat doses of UNO prolonged survival in combination with anti-PD-1 compared to gNO alone. With regard to tumor volume, statistically significant reductions were observed with repeat dosing of UNO versus anti-mPD-1 as a monotherapy and in combination with anti-CTLA-4 versus anti-CTLA-4 alone. Additionally, the data shows that short exposures between 10 seconds to one minute of tumor cells to UNO at increasing concentrations of 25,000 ppm to 100,000 ppm NO significantly upregulate mPD-L1 expression in a dose and time-dependent manner. Also, in vivo experiments exhibited a statistically significant day 1 increase in M1 macrophages, decrease in Tregs, and reduction in tumor cell viability was directionally maintained through day 5. We believe that together with the known ability of NO to activate and recruit the immune system, the data presented at this year’s AACR annual meeting appears to indicate that repeat dosing of UNO is feasible and may be effective even in difficult-to-treat, non-immunogenic tumor types.
In October 2023, Beyond Cancer presented positive pre-clinical data at the EORTC International Conference on Molecular Targets and Cancer Therapeutics, demonstrating a statistically significant survival benefit in mice treated with UNO plus anti-PD1 versus anti-PD1 alone. This was a pooled analysis of multiple studies done with 50,000 or 100,000 ppm NO for a single administration of 5 or 10 minutes. Additionally, Beyond Cancer’s second manuscript was published in the Cells Journal in an article titled “Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice.”
| 32 |
In late December 2023, the Company’s safety review committee completed its review of the first 6 human subjects treated with UNO and reported that there were no dose limiting toxicities at the 25,000 ppm NO concentration and the study may progress to the next concentration of 50,000 ppm NO.
In June 2024 at the American Society of Clinical Oncology (ASCO), the Company presented single agent treatment in relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous malignancies at UNO doses of 25,000 and 50,000 parts per million. The immune biomarker data at Day 21, following a single 5 minute dose of UNO 50,000 ppm, demonstrated increases in dendritic cells, cytotoxic T-cells, central memory T-cells and a favorable increase in the M1/M2 ratio. Myeloid Derived Suppressor Cells (MDSCs) also showed a 54% decrease. In the 25,000 ppm cohort, the same stimulatory immune biomarkers were upregulated. UNO was generally well tolerated with primarily Grade 1 related toxicities. One Grade 3 adverse event was deemed a dose limiting toxicity in the 50,000 ppm cohort resulting in the expansion of the cohort to six total subjects.
The Company also reported a case of relapsed/refractory Triple Negative Breast Cancer (TNBC) in which the subject showed no evidence of malignancy in a satellite lesion 21 days following UNO treatment and a corollary, rapid and durable clinical resolution of radiation-induced dermatitis.
A Phase 1b trial protocol has been submitted to the Israeli Ministry of Health (IMOH) and upon regulatory approval, this trial will enroll up to 20 subjects with prior exposure to anti-PD-1 antibody that have either progressed, not achieved a response, or have prolonged stable disease ( 12 weeks) on single agent anti-PD-1 without radiographic evidence of continued tumor reduction. Subjects enrolled in the Phase 1b trial will be treated with the UNO + anti-PD-1 combination.
Selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions in collaboration with Hebrew University of Jerusalem
On June 15, 2023, we announced that we had entered into an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, LTD. (the “University”) to acquire the commercial rights for neuronal nitric oxide synthase (nNOS) inhibitors being developed for the treatment of autism spectrum disorder (“ASD”) and other neurological conditions. Currently, there are no FDA-approved therapies utilizing nNOS inhibitors specifically for the treatment of ASD. Under the terms of the agreement, Beyond Air will make payments to the University over the two-year period from the date of the agreement for preclinical work. Also, we will pay a low single-digit royalty on net sales and certain one-time payments based on clinical, regulatory and sales milestones.
Work is currently being done by the University in a preclinical setting. We expect the program to progress into a phase 1 first-in-human clinical trial prior to the end of calendar year 2025.
Critical Accounting Estimates
A summary of our critical accounting estimates is discussed in the section entitled “Critical Accounting Estimates” in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Form 10-K. There were no material changes to our critical accounting estimates for the six months ended September 30, 2024.
| 33 |
Results of Operations and Comprehensive Loss
Below are the results of operations for the three and six months ended September 30, 2024 and September 30, 2023:
(in thousands)
| For the Three Months Ended | For the Six Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenue | $ | 798 | $ | 239 | $ | 1,481 | $ | 298 | ||||||||
| Cost of revenue | 1,882 | 432 | 2,897 | 735 | ||||||||||||
| Gross loss | (1,084 | ) | (193 | ) | (1,416 | ) | (437 | ) | ||||||||
| Research and development | (4,585 | ) | (7,130 | ) | (10,594 | ) | (11,826 | ) | ||||||||
| General and administrative | (7,163 | ) | (10,211 | ) | (14,402 | ) | (21,147 | ) | ||||||||
| Operating expenses | (11,748 | ) | (17,342 | ) | (24,995 | ) | (32,972 | ) | ||||||||
| Operating loss | (12,833 | ) | (17,535 | ) | (26,412 | ) | (33,410 | ) | ||||||||
| Other income (loss) | ||||||||||||||||
| Dividend/interest income | 150 | 641 | 511 | 1,050 | ||||||||||||
| Interest and finance expense | (927 | ) | (914 | ) | (1,891 | ) | (1,072 | ) | ||||||||
| Change in fair value of warrant liability | (4 | ) | 324 | 214 | 647 | |||||||||||
| Change in fair value of derivative liability | 256 | 500 | 1,314 | 1,012 | ||||||||||||
| Foreign exchange gain/(loss) | 74 | (42 | ) | (72 | ) | (34 | ) | |||||||||
| Loss on disposal of fixed assets | (171 | ) | - | (171 | ) | - | ||||||||||
| Loss on extinguishment of debt | (624 | ) | - | (624 | ) | - | ||||||||||
| Estimated liability for contingent loss | - | (400 | ) | - | (598 | ) | ||||||||||
| Other income / (expense) | 49 | - | 48 | (77 | ) | |||||||||||
| Total other income (expense) | (1,196 | ) | 109 | (671 | ) | 929 | ||||||||||
| Benefit from income taxes | - | - | - | - | ||||||||||||
| Net loss | $ | (14,029 | ) | $ | (17,426 | ) | $ | (27,083 | ) | $ | (32,481 | ) | ||||
| Less : net loss attributable to non-controlling interests | (671 | ) | (1,205 | ) | (1,525 | ) | (2,165 | ) | ||||||||
| Net loss attributable to Beyond Air, Inc. | (13,358 | ) | (16,220 | ) | (25,559 | ) | (30,315 | ) | ||||||||
| Foreign currency translation loss | (79 | ) | (35 | ) | 24 | (9 | ) | |||||||||
| Comprehensive loss attributable to Beyond Air, Inc. | $ | (13,438 | ) | $ | (16,255 | ) | $ | (25,535 | ) | $ | (30,325 | ) | ||||
| Net basic and diluted loss per share attributable to Beyond Air, Inc. | $ | (0.28 | ) | $ | (0.51 | ) | $ | (0.55 | ) | $ | (0.96 | ) | ||||
| Weighted average number of shares, outstanding, basic and diluted | 47,118,535 | 31,800,492 | 46,513,005 | 31,592,880 | ||||||||||||
| 34 |
Comparison of Three and Six Months Ended September 30, 2024 with the Three and Six Months Ended September 30, 2023
Revenues and Cost of Revenues
$0.8 million and $0.2 million revenue was recognized for the three months ended September 30, 2024 and September 30, 2023, respectively. Cost of revenue of $1.9 million and gross losses of $1.1 million were recognized for the three months ended September 30, 2024, compared to a cost of revenue of $0.4 million and gross losses of $0.2 million for the three months ended September 30, 2023.
$1.5 million and $0.3 million revenue was recognized for the six months ended September 30, 2024 and September 30, 2023, respectively. Cost of revenue of $2.9 million and gross losses of $1.4 million were recognized for the six months ended September 30, 2024, compared to a cost of revenue of $0.7 million and gross losses of $0.4 million for the six months ended September 30, 2023.
Revenues continue to expand as we continue to sign hospital contracts. Cost of revenue exceeded revenue primarily due to one time costs required to upgrade our existing fleet of devices, provisions for excess inventory and depreciation of devices purchased but not yet deployed.
Research and Development Expenses
Research and development expenses for the three months ended September 30, 2024 were $4.6 million as compared to $7.1 million for the three months ended September 30, 2023. The decrease of $2.5 million was primarily attributed to a decrease in spend in salaries $0.6 million ($0.7 million in Beyond Air offset by an increase of $0.1 million in Beyond Cancer), stock-based compensation ($0.5 million in Beyond Air and $0.5 million in Beyond Cancer), pre-clinical studies ($1.0 million related to Beyond Cancer offset by an increase in spend of $0.2 million in NeuroNos), professional fees ( $0.4 million in Beyond Cancer offset by an increase spend in Beyond Air $0.1 million), travel expenses $0.1 million in Beyond Air, offset by an increased spend related to clinical studies $0.2 million.
Research and development expenses for the six months ended September 30, 2024 were $10.6 million as compared to $11.8 million for the six months ended September 30, 2023. The decrease of $1.2 million was attributed primarily to a decreased in stock compensation $1.6 million (of which $0.8 million related to Beyond Air and $0.8 million related to Beyond Cancer), pre-clinical expenses $0.6 million (of which $0.9 million was Beyond Cancer offset by an increase in spend of $0.3 million for Autism), professional fees $0.3 million in Beyond Cancer, offset by an increase in salaries $0.3 million (of which was increased spend in Beyond Cancer of $0.6 million offset by a decrease in Beyond Air of $0.3 million) and clinical spend ($0.9 million in Beyond Air offset by a decreased spend in Beyond Cancer $0.1 million).
Selling, General and Administrative Expenses
Selling, general and administrative expenses for the three months ended September 30, 2024 and September 30, 2023 were $7.2 million and $10.2 million, respectively. The decrease of $3.0 million was attributed primarily to a decrease of $2.4 million due to stock based compensation cost (of which $1.2 million related to Beyond Air and $1.2 million related to Beyond Cancer), $0.2 million marketing and advertising costs for Beyond Air, $0.2 million of legal fees and $0.2 million of travel expenses.
Selling, general and administrative expenses for the six months ended September 30, 2024 and September 30, 2023 were $14.4 million and $21.1 million, respectively. The decrease of $6.7 million was attributed primarily to a decrease in stock-based compensation ($2.2 million in Beyond Air and $2.3 million in Beyond Cancer), salaries ($1.3 million in Beyond Air offset by an increase in Beyond Cancer of $0.8 million), $0.8 million in consulting fees $0.3 million travel expenses, $0.2 million rent, $0.1 million marketing and advertising costs and $0.1 million legal fees.
Other Income/Expense
Other expense for the three months ended September 30, 2024, and September 30, 2023 was an expense of $1.2 million and income of $0.1 million, respectively. The increase in expense of $1.3 million was attributed primarily to decreased dividend and interest income of $0.5 million, $0.6 million related to the loss on partial extinguishment of the Loan and Security agreement Agreement (the “Loan and Security Agreement”) with Avenue Capital Management II, L.P., as administrative agent and collateral agent (the “Agent”), Avenue Venture Opportunities Fund, L.P., a Delaware limited partnership (“Avenue”), and Avenue Venture Opportunities Fund II, L.P, a Delaware limited partnership (“Avenue 2” and, together with Avenue, the “Lenders”), a change in fair value of the derivative liability on the Loan and Security Agreement of $0.2 million and a change in fair value of the warrant liability on the Loan and Security Agreement of $0.3 million, $0.2 million losses incurred on disposal of fixed assets in relation to office closures offset by a decrease of $0.4 million relating to non-product related litigation and a decrease in foreign exchange losses $0.1 million.
Other income/(expense) for the six months ended September 30, 2024, and September 30, 2023 was an expense of $0.7 million and income of $0.9 million, respectively. The $1.6 million decrease in income is mainly due to a change in fair value of warrant liability of $0.4 million on the Loan and Security Agreement, in addition to $0.5 million of interest and dividend income from our investments in marketable securities, $0.6 million related to the loss on partial extinguishment of the Loan and Security agreement, an increase in interest expense of $0.8 million and offset by a decrease of $0.6 million of non-product related litigation and change in fair value of the derivative liability of $0.3 million on the Loan and Security Agreement.
Net Loss Attributable to Non-controlling Interests
Net loss attributed to non-controlling interests for the three months ended September 30, 2024, was $0.7 million, compared to $1.2 million for the three months ended September 30, 2023. Net loss attributed to non-controlling interests for the six months ended September 30, 2024, was $1.5 million, compared to $2.2 million for the six months ended September 30, 2023. Non-controlling interests represent 20% of the net loss of our Beyond Cancer subsidiary, which was established in November 2021.
| 35 |
Net Loss Attributed to Common Stockholders
Net loss attributed to common stockholders of Beyond Air, Inc for the three months ended September 30, 2024, was ($13.4) million or a loss of ($0.28) per share, basic and diluted. Our net loss attributed to common stockholders of Beyond Air, Inc for the three months ended September 30, 2023 was ($16.2) million or a loss of ($0.51) per share, basic and diluted.
Net loss attributed to common stockholders of Beyond Air, Inc for the six months ended September 30, 2024, was ($25.6) million or a loss of ($0.55) per share, basic and diluted. Our net loss attributed to common stockholders of Beyond Air, Inc for the six months ended September 30, 2023 was ($30.3) million or a loss of ($0.96) per share, basic and diluted.
Liquidity and Capital Resources
Cash Flows
Below is a summary of our cash flows activities for the six months ended September 30, 2024 and September 30, 2023:
| Six Months Ended | ||||||||
| September 30, | ||||||||
| (in thousands) | 2024 | 2023 | ||||||
| Net cash provided by (used in): | ||||||||
| Operating activities | $ | (23,528 | ) | $ | (31,472 | ) | ||
| Investing activities | 19,261 | (11,421 | ) | |||||
| Financing activities | 21,360 | 22,036 | ||||||
| Effect of exchange rate changes on cash and cash equivalents | (23 | ) | (19 | ) | ||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | $ | (17,069 | ) | $ | (20,876 | ) | ||
Operating Activities
For the six months ended September 30, 2024 the net cash used in operating activities was $23.5 million which was primarily due to our net loss of $27.1 million, which includes $6.6 million of stock-based compensation, $0.4 million received in grant payments, $1.5 million of depreciation and amortization, $3.9 million of accrued expenses (which included ($4.5) million of the payment of the final tranche of the Circassia settlement and ($2.9) million for the Hudson Bay settlement and ($7.6) million attributable to the resolution of Empery Asset Master, Ltd. Et AL, vs AIT Therapeutics Inc.)
For the six months ended September 30, 2023 the net cash used in operating activities was $31.5 million which was primarily due to our net loss of $32.5 million, which includes $12.6 million of stock-based compensation, $0.4 million received in grant payments, $0.7 million of depreciation and amortization and $1.3 million decrease in accounts payable, partially offset by ($3.5) million of the payment of the second tranche of the Circassia settlement and ($2.9) million for the Hudson Bay settlement and ($7.6) million attributable to the resolution of Empery Asset Master, Ltd. Et AL, vs AIT Therapeutics Inc.
Investing Activities
For the six months ended September 30, 2024, net cash provided by investing activities was $19.3 million. For the six months ended September 30, 2023, net cash used in investing activities was $11.4 million. In the six months ended September 30, 2024, the Company redeemed a net $23 million of excess cash in high quality, short term, U.S. dollar denominated marketable equities with high liquidity and invested $3.9 million for the purchase of property and equipment, mainly LungFit PH devices. In the six months ended September 30, 2023, the Company invested $8.9 million of excess cash in high quality, short term, U.S. dollar denominated marketable equities with high liquidity, and $2.5 million for the purchase of property and equipment, mainly LungFit PH devices.
Financing Activities
Net cash provided by financing activities for the six months ended September 30, 2024 was $21.4 million, mainly from the issuance of securities through securities purchase agreements which the net proceeds were $19 million, $7.5 million advance payment on loan and security agreement, and the issuance of common stock in connection with the At-The-Market Offering Sales Agreement with Truist Securities, Inc (the “2022 ATM”) of $0.6 million partially offset by $5.7 million from the payment of short-term loans, including a $5.0 million partial repayment to Avenue Capital. Net cash provided by financing activities for the six months ended September 30, 2023 was $22.0 million, mainly from the Loan and Security Agreement of which the net proceeds were $15.8 million, and the issuance of common stock in connection with the 2022 ATM of $6.7 million partially offset by $0.5 million from the payment of short-term loans.
Future Funding Requirements
We have generated revenue of $2.6 million from the sale of products to date. We had an operating cash flow decrease of $23.5 million for the six months ended September 30, 2024 and we have experienced an accumulated loss of $265.2 million since inception through September 30, 2024. As of September 30, 2024, we had cash, cash equivalents and marketable securities of $28.4 million ($22.6 million excluding Beyond Cancer) and $0.2 million in restricted cash. Management believes these factors raise substantial doubt about the Company’s ability to meet its obligations with cash on hand, however, management believes this doubt is alleviated through plans for increased revenues and decreased expenditures, many of which have already been implemented, enabling increased cash flows. The company has recently signed agreements with TrillaMed (providing access to Department of Defense and Veterans Affairs hospitals), Healthcare Links (expanding access to group purchasing organizations and integrated delivery networks) and Business Asia Consultants (accelerating global expansion) which will drive increased revenues. The company has implemented a capital conservation strategy, reducing our back office footprint, reducing staffing levels by over 30% across the company, placing our VCAP study on hold pending future funding and adjusting our production forecasts. The Company expects an immediate benefit from these actions.
Management is confident that the efforts it has implemented to increase revenues and decrease expenditures, while not assured, will enable the Company to meet its obligations.
| 36 |
Our future capital needs and the adequacy of our available funds will depend on many factors, including, but not necessarily limited to, the cost and time necessary for the development, preclinical studies, clinical trials and certification or regulatory approval of our other medical devices, indications as well as the commercial success of our approved product and any product candidates that receive marketing approval by the FDA. We may be required to raise additional funds through sale of equity or debt securities or through strategic collaborations and/or licensing agreements in order to fund operations until we are able to generate enough product or royalty revenues, if any. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could have a material adverse effect on our strategic objectives, results of operations and financial condition.
On May 25, 2021, the Company and Circassia Limited and its affiliates (collectively “Circassia”) entered into a settlement agreement (“the Settlement Agreement”) resolving all claims by and between the parties and mutually terminating the agreement with Circassia disclosed in Note 8 above. Pursuant to the terms of the Settlement Agreement, the Company agreed to pay Circassia $10.5 million in three installments. The first payment of $2.5 million was triggered upon FDA approval for the LungFit® PH (fixing the Initial Payment Due Date at July 28, 2022). Thereafter, the Company paid $3.5 million to Circassia on the first anniversary of the Initial Payment Due Date and $4.5 million on the second anniversary of the Initial Payment Due Date, which was in the second fiscal quarter of 2025. Additionally, beginning in the third fiscal quarter of 2025, Circassia will receive a quarterly royalty payment equal to 5% of LungFit® PH net sales in the U.S. until the final $6.0 million has been paid.
On February 4, 2022, we entered into an At-The-Market Equity Offering Sales Agreement with Truist Securities, Inc. and Oppenheimer & Co, Inc. (the “2022 ATM”). Under the 2022 ATM, we may sell shares of our common stock having aggregate sales proceeds of up to $50.0 million, from time to time and at various prices. Pursuant to the “baby shelf rules” promulgated by the SEC, if our public float is less than $75.0 million as of specified measurement periods, the number of shares of common stock that may be offered and sold by us under a Form S-3 registration statement, including pursuant to the 2022 ATM, in any twelve-month period is limited to an aggregate amount that does not exceed one-third of our public float. As of September 30, 2024, due to the SEC’s “baby shelf rules,” we were permitted to sell up to $10.5 million of shares of common stock pursuant to the 2022 ATM. We will remain subject to the “baby shelf rules” under the Form S-3 registration statement until such time as our public float exceeds $75.0 million. If shares of our common stock are sold, there is a 3% fee paid to the sales agent.
On June 15, 2023 (the “Closing Date”), the Company and its wholly owned subsidiary, Beyond Air Ltd. entered into a Loan and Security Agreement (the “LSA”) with Avenue Capital Management II, L.P., as administrative agent and collateral agent (the “Agent”), Avenue Venture Opportunities Fund, L.P., a Delaware limited partnership (“Avenue”), and Avenue Venture Opportunities Fund II, L.P, a Delaware limited partnership (“Avenue 2” and, together with Avenue, the “Lenders”). Also on June 15, 2023, the Company entered into a Supplement to the LSA (collectively with the Agreement, the “Loan Agreement”) with the Agent and the Lenders for senior secured term loans, with $17.5 million advanced on the Closing Date. On September 30, 2024 Beyond Air and Avenue Capital Management II, L.P., Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. (“collectively, Avenue Capital”) reached an agreement to extinguish the Avenue Capital senior secured term loan for a one-time payment of $17.85 million. This agreement eliminates the debt and interest payments that would have been made to Avenue Capital from October 1, 2024 through June 30, 2026 of $12.0 million. In connection with this agreement $5.0 million was paid on September 27, 2024 in partial settlement. The final $12.85million was paid on October 4, 2024. Avenue Capital invested $3.35 million in the securities purchase agreement II at the same terms and conditions as all other investors.
On September 27, 2024, we entered into a binding term sheet for a secured loan with certain lenders including our Chief Executive Officer Steven Lisi and director Robert Carey. The Term Sheet was approved by each of our independent and disinterested directors, following the receipt of a recommendation from an independent investment bank. The Term Sheet provides for the following expected terms: (i) principal amount of $11,500,000; (ii) ten-year term; (iii) interest of 15% per annum of which 12% shall be payable in kind through July 2026; (iv) a royalty interest of 8% of our net sales on a quarterly basis from July 2026 until the facility is repaid in full; and (v) we shall issue the lenders warrants to purchase shares of common stock at an exercise price of $0.3793 per share, in an aggregate amount equal to the quotient of the principal divided by the exercise price. The Company finalized this loan and security agreement on November 1, 2024. (See Note 14)
Our ability to continue to operate beyond the third fiscal quarter of 2026 will be largely dependent upon the successful commercial launch of LungFit® PH, as well as obtaining partners in other parts of the world, and raising additional funds to finance our activities until we are generating cash flow from operations. Further, there are no assurances that we will be successful in obtaining an adequate level of financing for the development and commercialization of our other product candidates.
There are numerous risks and uncertainties associated with the development of our NO delivery system and we are unable to estimate the amounts of increased capital outlays and operating expenses associated with the completion of the research and development of our product candidates.
| 37 |
Our future capital requirements will depend on many factors, including:
| ● | the progress and costs of our preclinical studies, clinical trials and other research and development activities; |
| ● | the costs of commercializing the LungFit® system; |
| ● | the scope, prioritization and number of our clinical trials and other research and development programs; |
| ● | the costs and timing of obtaining certification or regulatory approval for our product candidates; |
| ● | the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights; |
| ● | the costs of, and timing for, strengthening our manufacturing agreements for production of sufficient clinical quantities of our product candidates; |
| ● | the potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally; |
| ● | the costs of acquiring or undertaking the development and commercialization efforts for additional, future therapeutic applications of our product candidates; |
| ● | the magnitude of our general and administrative expenses; and |
| ● | any cost that we may incur under current and future in-and-out-licensing arrangements relating to our product candidates. |
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of foreign currency exchange rates.
ITEM 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based upon our evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2024.
Changes in Internal Control Over Financial Reporting
During the three months ended September 30, 2024, there were no changes made to our internal control over financial reporting that materially affected, or that are reasonably likely to materially affect our internal control over financial reporting.
| 38 |
PART II OTHER INFORMATION
ITEM 1. Legal Proceedings
None.
ITEM 1A. Risk Factors
There have been no material changes to the risk factors previously disclosed in Part I, “Item 1A. Risk Factors” of our 2024 Annual Report except as set forth below.
If we are unable to maintain listing of our securities on the Nasdaq Capital Market, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and it may be more difficult for our shareholders to sell their securities.
Although our common stock is currently listed on the Nasdaq Capital Market, we may not be able to continue to meet the exchange’s minimum listing requirements or those of any other national exchange. If we are unable to maintain our listing on the Nasdaq Capital Market, our common stock may be thinly traded.
On August 8, 2024, the Company received a letter from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been given 180 calendar days, or until February 4, 2025, to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance with the Minimum Bid Price Requirement by February 4, 2025, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market with the exception of the Minimum Bid Price Requirement and will need to provide written notice of its intention to cure the deficiency during such additional compliance period, by effecting a reverse split of its common stock, if necessary. If it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for the additional compliance period, and the Company does not regain compliance by February 4, 2025, Nasdaq will provide written notification to the Company that its common stock is subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules.
If Nasdaq determines to delist our securities from trading on its exchange and we are unable to obtain listing on another national securities exchange, a reduction in some or all of the following may occur, each of which could have a material adverse effect on our shareholders:
| ● | the liquidity of our common stock; | |
| ● | the market price of our common stock; | |
| ● | our ability to obtain financing for the continuation of our operations; | |
| ● | the number of investors that will consider investing in our common stock; | |
| ● | the number of market makers in our common stock; | |
| ● | the availability of information concerning the trading prices and volume of our common stock; and |
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds
ITEM 3. Defaults Upon Senior Securities
None.
ITEM 4. Mine Safety Disclosures
Not applicable.
ITEM 5. Other Information
Rule 10b5-1 Trading Arrangement
During the three months ended September 30, 2024,
no director or officer of the Company
| 39 |
ITEM 6. Exhibits.
* Filed herewith.
** Furnished herewith.
| 40 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| BEYOND AIR, INC. | |
| /s/ Steven Lisi | |
| Date: November 11, 2024 | Steven Lisi |
| President and Chief Executive Officer | |
| (Principal Executive Officer) | |
| /s/ Douglas Larson | |
| Date: November 11, 2024 | Douglas Larson |
| Chief Financial Officer | |
| (Principal Financial and Accounting Officer) |
| 41 |